<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18714345</article-id><article-id pub-id-type="pmc">2500163</article-id><article-id pub-id-type="publisher-id">08-PONE-RA-04775R1-A</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0003003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Virology/Immunodeficiency Viruses</subject><subject>Virology/New Therapies, including Antivirals and Immunotherapy</subject><subject>Pathology/Molecular Pathology</subject></subj-group></article-categories><title-group><article-title>HIV Replication Enhances Production of Free Fatty Acids, Low Density Lipoproteins and Many Key Proteins Involved in Lipid Metabolism: A Proteomics Study</article-title><alt-title alt-title-type="running-head">HIV Lipid Metabolism</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rasheed</surname><given-names>Suraiya</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Jasper S.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Lau</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Arvan S.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1">
<addr-line>Laboratory of Viral Oncology, AIDS and Proteomics Research, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Nixon</surname><given-names>Douglas F.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of California San Francisco, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>srasheed@usc.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: SR. Performed the experiments: SR AL. Analyzed the data: SR JSY AL ASC. Contributed reagents/materials/analysis tools: SR. Wrote the paper: SR.</p></fn></author-notes><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>20</day><month>8</month><year>2008</year></pub-date><volume>3</volume><issue>8</issue><elocation-id>e3003</elocation-id><history><date date-type="received"><day>20</day><month>5</month><year>2008</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2008</year></date></history><permissions><copyright-statement>Rasheed et al.</copyright-statement><copyright-year>2008</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>HIV-infected patients develop multiple metabolic abnormalities including insulin resistance, lipodystrophy and dyslipidemia. Although progression of these disorders has been associated with the use of various protease inhibitors and other antiretroviral drugs, HIV-infected individuals who have not received these treatments also develop lipid abnormalities albeit to a lesser extent. How HIV alters lipid metabolism in an infected cell and what molecular changes are affected through protein interaction pathways are not well-understood.</p></sec><sec><title>Results</title><p>Since many genetic, epigenetic, dietary and other factors influence lipid metabolism <italic>in vivo</italic>, we have chosen to study genome-wide changes in the proteomes of a human T-cell line before and after HIV infection in order to circumvent computational problems associated with multiple variables. Four separate experiments were conducted including one that compared 14 different time points over a period of &#x0003e;3 months. By subtractive analyses of protein profiles overtime, several hundred differentially expressed proteins were identified in HIV-infected cells by mass spectrometry and each protein was scrutinized for its biological functions by using various bioinformatics programs. Herein, we report 18 HIV-modulated proteins and their interaction pathways that enhance fatty acid synthesis, increase low density lipoproteins (triglycerides), dysregulate lipid transport, oxidize lipids, and alter cellular lipid metabolism.</p></sec><sec><title>Conclusions</title><p>We conclude that HIV replication alone (i.e. without any influence of antiviral drugs, or other human genetic factors), can induce novel cellular enzymes and proteins that are significantly associated with biologically relevant processes involved in lipid synthesis, transport and metabolism (p&#x0200a;=&#x0200a;&#x0003c;0.0002&#x02013;0.01). Translational and clinical studies on the newly discovered proteins may now shed light on how some of these proteins may be useful for early diagnosis of individuals who might be at high risk for developing lipid-related disorders. The target proteins could then be used for future studies in the development of inhibitors for preventing lipid-metabolic anomalies. This is the first direct evidence that HIV-modulates production of proteins that are significantly involved in disrupting the normal lipid-metabolic pathways.</p></sec></abstract><counts><page-count count="15"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>In the past two decades, the use of highly active antiretroviral therapy (HAART) has minimized the global incidence of the acquired immunodeficiency syndrome (AIDS) by reducing the viral load in HIV-infected individuals <xref rid="pone.0003003-Carr1" ref-type="bibr">[1]</xref>&#x02013;<xref rid="pone.0003003-Carter1" ref-type="bibr">[4]</xref>. However, a significant number of patients on HAART develop multiple metabolic complications and are at high risk for developing many chronic diseases including insulin resistance, coronary artery disease, renal diseases, lipodystrophy and dyslipidemia to name a few <xref rid="pone.0003003-Carr1" ref-type="bibr">[1]</xref>, <xref rid="pone.0003003-Fisher1" ref-type="bibr">[2]</xref>, <xref rid="pone.0003003-Constans1" ref-type="bibr">[5]</xref>&#x02013;<xref rid="pone.0003003-Raulin1" ref-type="bibr">[14]</xref>. Although lipodystrophy is a rare disease in the general population, it is significantly common in HIV-infected individuals who have been treated with various combination therapies <xref rid="pone.0003003-Raulin1" ref-type="bibr">[14]</xref>&#x02013;<xref rid="pone.0003003-Lorenz1" ref-type="bibr">[21]</xref>. In addition, many HIV-infected individuals who have <italic>not</italic> received any treatment also develop hyperlipidemia, hypertension, diabetes, insulin resistance, and other metabolic complications <xref rid="pone.0003003-Coll1" ref-type="bibr">[10]</xref>, <xref rid="pone.0003003-Umpleby1" ref-type="bibr">[16]</xref>, <xref rid="pone.0003003-Lorenz1" ref-type="bibr">[21]</xref>.</p><p>Lipodystrophy was initially characterized as the wasting syndrome with selective loss of body fat or lipoatrophy (thinning of arms, legs and face) central adiposity and accumulation of fat in the breast tissue or the back of the neck (buffalo hump) <xref rid="pone.0003003-Gomez1" ref-type="bibr">[22]</xref>, <xref rid="pone.0003003-Carr3" ref-type="bibr">[23]</xref>. The clinical profile of this disease has now been expanded to include dyslipidemia, hyperglycemia, hypercholesterolemia, hepatomegaly, glomerulonephritis and other metabolic syndromes <xref rid="pone.0003003-Carter1" ref-type="bibr">[4]</xref>, <xref rid="pone.0003003-Tanwani1" ref-type="bibr">[6]</xref>, <xref rid="pone.0003003-Barbaro2" ref-type="bibr">[15]</xref>, <xref rid="pone.0003003-Carr2" ref-type="bibr">[18]</xref>, <xref rid="pone.0003003-Currier1" ref-type="bibr">[20]</xref>, <xref rid="pone.0003003-Gomez1" ref-type="bibr">[22]</xref>, <xref rid="pone.0003003-Grinspoon1" ref-type="bibr">[24]</xref>&#x02013;<xref rid="pone.0003003-Vigouroux1" ref-type="bibr">[26]</xref>. Once the symptomatic disease is established in HIV-infected patients, it is difficult to reverse the condition in these individuals <xref rid="pone.0003003-Mallon1" ref-type="bibr">[27]</xref>.</p><p>Although molecular mechanisms responsible for the numerous lipid-related disorders in HIV-infected individuals are not well understood , treatment with nucleoside reverse transcriptase inhibitors (NRTI's) has been reported to affect mitochondrial functions by depletion of its DNA and inhibiting transcription <xref rid="pone.0003003-Mallon1" ref-type="bibr">[27]</xref>. On the other hand, protease inhibitors (PI's) bind to catalytic domains of the HIV protease and inhibit virus replication <xref rid="pone.0003003-Carter1" ref-type="bibr">[4]</xref>, <xref rid="pone.0003003-Carr2" ref-type="bibr">[18]</xref>, <xref rid="pone.0003003-Carr3" ref-type="bibr">[23]</xref>, <xref rid="pone.0003003-Mallon1" ref-type="bibr">[27]</xref>, <xref rid="pone.0003003-Behrens2" ref-type="bibr">[28]</xref>. PI's also bind to the low-density lipoprotein-receptor-related protein (LRP) and cytoplasmic retinoic-acid binding protein type 1 (CRABP1), both of which show 60&#x00025; sequence homologies to HIV protease <xref rid="pone.0003003-Carr2" ref-type="bibr">[18]</xref>. Since these proteins regulate lipid metabolism, the binding of PI's to LRP and CRABP1 impairs chylomicron uptake and triglyceride clearance <xref rid="pone.0003003-Carr2" ref-type="bibr">[18]</xref>, <xref rid="pone.0003003-Carr3" ref-type="bibr">[23]</xref>. In addition, adipocyte toxicity has also been reported due to PI's interference with the functions of the transcription factor and the sterol regulatory element binding protein 1C <xref rid="pone.0003003-Mallon1" ref-type="bibr">[27]</xref>.</p><p>Among the numerous cell types that are susceptible to HIV infection <italic>in vivo</italic>, the T-cells, monocytes, macrophages, follicular dendritic cells are primarily responsible for the enhanced replication of the virus in the body. Although adipocytes can be infected by HIV <italic>in vitro</italic> or <italic>in vivo</italic>, these cells are not uniformly infected and the virus replication is slow because most adipocytes are quiescent cells. Exposure of these cells to cytokines or other factors produced by a variety of cell types infected by HIV (or other pathogenic organisms) activates expression of HIV receptors needed for the infection and replication <xref rid="pone.0003003-Hazan1" ref-type="bibr">[29]</xref>&#x02013;<xref rid="pone.0003003-de1" ref-type="bibr">[32]</xref>. Further, adipose tissue is comprised of multiple cell types including adipocytes, monocytes, macrophages, endothelial and vascular smooth muscle cells <xref rid="pone.0003003-Desruisseaux1" ref-type="bibr">[30]</xref>, <xref rid="pone.0003003-de1" ref-type="bibr">[32]</xref>, <xref rid="pone.0003003-Xu1" ref-type="bibr">[33]</xref>. These immune cells are functionally active in the adipose tissues and produce numerous cytokines and other regulatory factors that influence endocrine and lipid metabolism <xref rid="pone.0003003-de1" ref-type="bibr">[32]</xref>, <xref rid="pone.0003003-Xu1" ref-type="bibr">[33]</xref>. The adipokines are also vital for lipid homeostasis, regulation of steroid hormones, prostaglandin and fat soluble vitamins <xref rid="pone.0003003-Desruisseaux1" ref-type="bibr">[30]</xref>, <xref rid="pone.0003003-Bonnet1" ref-type="bibr">[34]</xref>, <xref rid="pone.0003003-Rajala1" ref-type="bibr">[35]</xref>. These factors also control storage of excess lipids and triglycerides (both normal and abnormal fatty acids) present in the circulation <xref rid="pone.0003003-Bonnet1" ref-type="bibr">[34]</xref>, <xref rid="pone.0003003-Murray1" ref-type="bibr">[36]</xref>. Many infectious agents including HIV have profound effects on adipocytes which become dysfunctional and can not store most lipids /triglycerides properly. This causes additional lipid abnormalities and metabolic disorders in HIV-infected individuals <xref rid="pone.0003003-Currier1" ref-type="bibr">[20]</xref>, <xref rid="pone.0003003-Desruisseaux1" ref-type="bibr">[30]</xref>, <xref rid="pone.0003003-Ng1" ref-type="bibr">[37]</xref>. Therefore, it is important to note that even when adipocytes are infected by HIV <italic>in vivo,</italic> the multiple abnormalities seen in adipose tissues of HIV-1-infected individuals are not due to the <italic>replication</italic> of HIV in adipocytes <italic>per se</italic>.</p><p>The viral envelope and cell surface membranes are made up of lipoproteins and cholesterols, and the fatty acids are synthesized in the cytoplasm. Both lipids and lipoproteins are required for molecular communication at each step of the virus replication, from its entry into the cell to integration, transcription, assembly and budding of virus particles from cell membranes <xref rid="pone.0003003-Raulin1" ref-type="bibr">[14]</xref>, <xref rid="pone.0003003-Ono1" ref-type="bibr">[38]</xref>&#x02013;<xref rid="pone.0003003-Brugger1" ref-type="bibr">[44]</xref>. While the bulk of lipids present in the circulation are contributed by the dietary fats, at least eight different types of lipids are synthesized in various cell types <xref rid="pone.0003003-Desruisseaux1" ref-type="bibr">[30]</xref>, <xref rid="pone.0003003-Xu1" ref-type="bibr">[33]</xref>, <xref rid="pone.0003003-Ng1" ref-type="bibr">[37]</xref>. The lipid-binding acyl proteins are catalyzed by a number of enzymes to make different types and amounts of lipids that are required for the construction of cellular membranes. Further, cholesterol efflux is a common phenomenon in HIV-infected lymphocytes and macrophages <xref rid="pone.0003003-Wang1" ref-type="bibr">[45]</xref>&#x02013;<xref rid="pone.0003003-Grunfeld1" ref-type="bibr">[48]</xref>.When excess lipids are synthesized they are leached out from various cell types (in circulation) and are stored in the adipocytes, preadipocytes , undifferentiated fibroblasts or mesenchymal connective tissue cells that are present in many organs <xref rid="pone.0003003-Desruisseaux1" ref-type="bibr">[30]</xref>, <xref rid="pone.0003003-de1" ref-type="bibr">[32]</xref>.</p><p>Recently several investigators have used RNA expression profiles, single nucleotide polymorphisms (SNP's) and proteomics technology to understand the inner workings of HIV-infected and uninfected cells. Whereas gene expression data provides vital genetic information <xref rid="pone.0003003-Bonnet1" ref-type="bibr">[34]</xref>, <xref rid="pone.0003003-Arnedo1" ref-type="bibr">[49]</xref>&#x02013;<xref rid="pone.0003003-Mallon2" ref-type="bibr">[51]</xref>, the mRNAs are modified post-transcriptionally and their products are altered post-translationally to give rise to disease-specific proteins. While a number of viral and cellular proteins involved in cell cycle, HIV-induced syncytia formation, apoptosis, and cytopathicity of infected macrophages have been identified by proteomics technology <xref rid="pone.0003003-Kadiu1" ref-type="bibr">[52]</xref>&#x02013;<xref rid="pone.0003003-Ringrose1" ref-type="bibr">[57]</xref>, molecular events involved in HIV-related lipid abnormalities have not yet been studied. Since the cellular systems and cellular milieu of proteins help in the synthesis, distribution and maintenance of lipid homeostasis within various tissues <xref rid="pone.0003003-Desruisseaux1" ref-type="bibr">[30]</xref>, <xref rid="pone.0003003-Rajala1" ref-type="bibr">[35]</xref>, we chose to study proteins involved in lipid metabolism by HIV infection alone without any influence of the genetic diversity of HIV and the human population it infects. A major consideration in the design of our experiments was to circumvent numerous computational problems associated with genetic and epigenetic variables (smoking, alcohol, fat-rich diet, diabetes, blood pressure, diabetes etc.) that influence lipid metabolism <italic>in vivo</italic>. Thus, we also avoided testing proteomes of mononuclear cells derived from freshly collected peripheral blood because the susceptibility of these genetically diverse cells to HIV infection would be different and the significance of variables would be difficult to assess in a heterogeneous human population. Likewise, we did not use primary HIV strains that are uniquely distinct as a quasispecies in each HIV-infected individual. In addition, HIV replication as well as disease outcomes are influenced by TNF and other cytokines produced by many pathogenic viruses such as hepatitis, herpes and other microbes that co-inhabit HIV infected individuals. Since efficient replication of the virus is essential to the disease development, we chose a single-cell clone of a human T-cell line (RH9) that is highly susceptible to HIV infection and studied changes in protein profiles due to infection with a biologically cloned HIV strain B (X4) <italic>in vitro</italic>
<xref rid="pone.0003003-Rasheed1" ref-type="bibr">[58]</xref>, <xref rid="pone.0003003-Jensen1" ref-type="bibr">[59]</xref>. Cellular proteins were analyzed by proteomics technology (two-dimensional gel electrophoresis (2DGE), image analyses, mass spectrometry, bioinformatics and statistical analyses. Multiple sets of proteomes were evaluated over a 3-year period including one experiment which compared 13&#x02013;14 different time points (starting at 1.5 hrs to 96 days post HIV-infection) over three months (see <xref ref-type="sec" rid="s3">materials and methods</xref>).</p><p>In this report we present the first direct evidence that HIV replication alone in human T-cells, without any influence of antiviral drugs or other factors, can stimulate production of novel cellular enzymes and proteins that enhance fatty acid synthesis, increase quantity of low density lipoproteins, secrete triglycerides, dysregulate lipid transport, oxidize lipids, and alter lipid metabolism. This data leads us to a new concept in HIV-induced disease mechanisms.</p></sec><sec id="s2"><title>Results and Discussion</title><sec id="s2a"><title>1. Identification of Differentially Regulated Proteins Post-HIV Infection</title><p>We have identified 18 proteins that have been differentially regulated after HIV infection <italic>in vitro</italic> (<xref ref-type="fig" rid="pone-0003003-g001">Figure 1</xref> &#x00026; <xref ref-type="table" rid="pone-0003003-t001">Tables 1</xref>&#x00026;<xref ref-type="table" rid="pone-0003003-t002">2</xref>). Stringent protocols were used to select lipid associated proteins from several hundred proteins that were upregulated, downregulated, or synthesized <italic>de novo</italic> in HIV-infected cells. All proteins were identified by Matrix Assisted Laser Desorption Time Of Flight (MALDI- TOF) mass spectrometry (MS) and confirmed from multiple gels. Biological functions of each protein were scrutinized by at least four investigators from the global public databases and by the use of several bioinformatics programs. The Ingenuity Systems' knowledgebase of the &#x0201c;Functional Repository of Human Genes and Proteins&#x0201d; was used to confirm proteins involved in different aspects of human lipid metabolism. The Ingenuity System was also used to calculate the likelihood of whether a specific lipid-related function in the &#x0201c;Global Functional Analysis&#x0201d; and &#x0201c;Global Canonical Pathways&#x0201d; is due to random chance or the given biological process in lipid metabolic pathway is statistically significant. Only those proteins that showed a p-value of &#x0003c;0.05 in relation to their effects on lipid metabolism were selected for further analyses. Each of the selected proteins could be categorically associated with one or more aspects of the lipid metabolism including the synthesis, production, secretion and transport of various fatty acids (<xref ref-type="fig" rid="pone-0003003-g001">Figure 1</xref>).</p><fig id="pone-0003003-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0003003.g001</object-id><label>Figure 1</label><caption><title>Diagram showing putative biological processes involved in lipid metabolism.</title><p>Each circle represents proteins associated with the respective function/s. Proteins in red were downregulated post-HIV infection (<xref ref-type="fig" rid="pone-0003003-g003">Figure 3</xref>). All other proteins were either expressed exclusively in HIV infected cells (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref>) or upregulated after virus infection (<xref ref-type="fig" rid="pone-0003003-g003">Figure 3</xref>). Full names, abbreviations and accession numbers of each protein are listed in <xref ref-type="table" rid="pone-0003003-t001">Tables 1</xref>&#x00026;<xref ref-type="table" rid="pone-0003003-t002">2</xref>.</p></caption><graphic xlink:href="pone.0003003.g001"/></fig><table-wrap id="pone-0003003-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0003003.t001</object-id><label>Table 1</label><caption><title>HIV- Modulated Enzymes and Kinases Associated with Fatty Acid Synthesis and Lipid Metabolism.</title></caption><alternatives><graphic id="pone-0003003-t001-1" xlink:href="pone.0003003.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Protein Name</td><td align="left" rowspan="1" colspan="1">Abbrev.</td><td align="left" rowspan="1" colspan="1">Acces. #</td><td align="left" rowspan="1" colspan="1">Putative Function</td><td align="left" rowspan="1" colspan="1">P-value</td><td align="left" rowspan="1" colspan="1">Location</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Long-chain-fatty-acid-CoA ligase 1 (synonym: Acyl-CoA synthetase 1)</td><td align="left" rowspan="1" colspan="1">ACSL1</td><td align="left" rowspan="1" colspan="1">P41215</td><td align="left" rowspan="1" colspan="1">Provides activated intermediates for complex lipid synthesis, protein modification, and beta-oxidation</td><td align="left" rowspan="1" colspan="1">0.005 to 0.02</td><td align="left" rowspan="1" colspan="1">mitochondria/endoplasmic reticulum/peroxisome/microsomal membrane</td></tr><tr><td align="left" rowspan="1" colspan="1">Complement C3 precursor</td><td align="left" rowspan="1" colspan="1">CO3 (C3)</td><td align="left" rowspan="1" colspan="1">P01024</td><td align="left" rowspan="1" colspan="1">Peptidase that promotes virus infection and fatty acid synthesis; cooperates with other lipogenic proteins in removal of triaclglycerols</td><td align="left" rowspan="1" colspan="1">0.0002 to 0.005</td><td align="left" rowspan="1" colspan="1">extra-cellular space</td></tr><tr><td align="left" rowspan="1" colspan="1">Fatty acid synthase</td><td align="left" rowspan="1" colspan="1">FAS (FASN)</td><td align="left" rowspan="1" colspan="1">P49327</td><td align="left" rowspan="1" colspan="1">Lipogenic enzyme:catalyzes formation of long-chain fatty acids</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">cytoplasm, melanosome</td></tr><tr><td align="left" rowspan="1" colspan="1">Glutathione peroxidase</td><td align="left" rowspan="1" colspan="1">GPX1</td><td align="left" rowspan="1" colspan="1">P07203</td><td align="left" rowspan="1" colspan="1">Antioxidant enzyme that detoxifies lipid hydroperoxides</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">cytoplasm</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein kinase C beta type</td><td align="left" rowspan="1" colspan="1">KPCB (PRKCB1)</td><td align="left" rowspan="1" colspan="1">P05771</td><td align="left" rowspan="1" colspan="1">Is involved in generation of phosphatidylethanolamine, a lipid found in biological membranes</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">cytoplasm, peripheral membrane</td></tr><tr><td align="left" rowspan="1" colspan="1">Phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing beta polypeptide</td><td align="left" rowspan="1" colspan="1">P3C2B (PIK3C2B)</td><td align="left" rowspan="1" colspan="1">O00750</td><td align="left" rowspan="1" colspan="1">Lipid kinase activity&#x02013; phosphorylates phosphatidylinositol in the cell membrane</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">plasma membrame, cytoplasm, microsome, nucleus</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein disulfide isomerase A3 precursor</td><td align="left" rowspan="1" colspan="1">PDIA3&#x0002a;</td><td align="left" rowspan="1" colspan="1">P30101</td><td align="left" rowspan="1" colspan="1">Essential for the formation of APOB;catalyzes rearrangement of -S-S- bonds in proteins</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">endoplasmic reticulum lumen, melanosome</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>All proteins except PDIA3 (<sup>&#x0002a;</sup>) were upregulated compared to the counterpart uninfected cells or were synthesized de novo in HIV-infected cells. Protein names, abbreviations, locations and accession numbers are from SwissProt and are presented in alphabetical order. Putative functions of each protein are related to biological processes involved in various aspects of lipid metabolism. Significance associated with lipid metabolism was calculated by Fisher Exact Test using software from Ingenuity Systems Inc. A p-value of &#x0003c;0.05 represents a statistically significant non-random association of a specific protein with a lipid-related function in the Global Functional Analysis.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0003003-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0003003.t002</object-id><label>Table 2</label><caption><title>HIV- Modulated Proteins Associated with Lipid Metabolism</title></caption><alternatives><graphic id="pone-0003003-t002-2" xlink:href="pone.0003003.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Protein Name</td><td align="left" rowspan="1" colspan="1">Abbrev.</td><td align="left" rowspan="1" colspan="1">Acces. #</td><td align="left" rowspan="1" colspan="1">Putative Function</td><td align="left" rowspan="1" colspan="1">P-value</td><td align="left" rowspan="1" colspan="1">Location</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Acyl-CoA-binding protein</td><td align="left" rowspan="1" colspan="1">ACBP&#x0002a;</td><td align="left" rowspan="1" colspan="1">P07108</td><td align="left" rowspan="1" colspan="1">Loss or deficiency of ACBP results in fatty acid metabolism abnormalities</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">cytoplasm; Ligand</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum albumin [Precursor]</td><td align="left" rowspan="1" colspan="1">ALBU (ALB)</td><td align="left" rowspan="1" colspan="1">P02768</td><td align="left" rowspan="1" colspan="1">Binds to fatty acids: lipid peroxidation and crystallization</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">Extra-cellular space; Transporter</td></tr><tr><td align="left" rowspan="1" colspan="1">Apolipoprotein A-I</td><td align="left" rowspan="1" colspan="1">APOA1</td><td align="left" rowspan="1" colspan="1">P02647</td><td align="left" rowspan="1" colspan="1">Involved in reverse transport of cholesterol from tissues; promotes cholesterol efflux from tissues; related to ipoprotein-modifying enzymes degrades APOB</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">Extra-cellular space;Transporter</td></tr><tr><td align="left" rowspan="1" colspan="1">Apolipoprotein B-100 [Precursor]</td><td align="left" rowspan="1" colspan="1">APOB</td><td align="left" rowspan="1" colspan="1">P04114</td><td align="left" rowspan="1" colspan="1">Major protein constituent of LDL and VLDL. Functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor; only protein to mobilize triacylglycerides</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">Extra-cellular space;Transporter</td></tr><tr><td align="left" rowspan="1" colspan="1">Fatty acid-binding protein, epidermal</td><td align="left" rowspan="1" colspan="1">FABPE (FABP5)</td><td align="left" rowspan="1" colspan="1">Q01469</td><td align="left" rowspan="1" colspan="1">High specificity for fatty acids. Involved in biosynthesis of phosphatidylcholine and other lipids</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">Adapter/Transporter</td></tr><tr><td align="left" rowspan="1" colspan="1">Heat shock 70 kDa protein 1-HOM</td><td align="left" rowspan="1" colspan="1">HS71L (HSPA1L)</td><td align="left" rowspan="1" colspan="1">P34931</td><td align="left" rowspan="1" colspan="1">Functions in protein folding; prolongs life of mature protein kinase C by allowing the enzyme to re-phosphorylate</td><td align="left" rowspan="1" colspan="1">0.0002</td><td align="left" rowspan="1" colspan="1">cytoplasm; Stress-induced Molecular Chaperone</td></tr><tr><td align="left" rowspan="1" colspan="1">Heat shock protein HSP 90-beta</td><td align="left" rowspan="1" colspan="1">HS90B (HSP90AB1)</td><td align="left" rowspan="1" colspan="1">P08238</td><td align="left" rowspan="1" colspan="1">molecular chaperone works with HS71L</td><td align="left" rowspan="1" colspan="1">0.0002</td><td align="left" rowspan="1" colspan="1">cytoplasm, melanosome; Stress-induced Molecular Chaperone</td></tr><tr><td align="left" rowspan="1" colspan="1">Low-density lipoprotein receptor-related protein 1 precursor</td><td align="left" rowspan="1" colspan="1">LRP1</td><td align="left" rowspan="1" colspan="1">Q07954</td><td align="left" rowspan="1" colspan="1">Receptor for aggregated LDL ; increases quantity of free fatty acids</td><td align="left" rowspan="1" colspan="1">0.0002 to 0.002</td><td align="left" rowspan="1" colspan="1">plasma membrane, cytoplasm, nucleus; Receptor</td></tr><tr><td align="left" rowspan="1" colspan="1">Low-density lipoprotein receptor-related protein 2 precursor</td><td align="left" rowspan="1" colspan="1">LRP2&#x0002a;</td><td align="left" rowspan="1" colspan="1">P98164</td><td align="left" rowspan="1" colspan="1">Regulates lipid metabolism, modulates multiple signaling pathways</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">membrane; Receptor</td></tr><tr><td align="left" rowspan="1" colspan="1">Stress-induced-phosphoprotein 1</td><td align="left" rowspan="1" colspan="1">STIP1&#x0002a;</td><td align="left" rowspan="1" colspan="1">P31948</td><td align="left" rowspan="1" colspan="1">Mediates the association of the molecular chaperones HSC70 and HSP90; downregulation may enhance lipid oxidation</td><td align="left" rowspan="1" colspan="1">0.0002</td><td align="left" rowspan="1" colspan="1">cytoplasm, nucleus;Adapter</td></tr><tr><td align="left" rowspan="1" colspan="1">Very low-density lipoprotein receptor precursor</td><td align="left" rowspan="1" colspan="1">VLDLR</td><td align="left" rowspan="1" colspan="1">P98155</td><td align="left" rowspan="1" colspan="1">Increases quantities of LDL and fatty acids; reduces clearance of triacylglycerol-rich lipids</td><td align="left" rowspan="1" colspan="1">0.0002 to 0.01</td><td align="left" rowspan="1" colspan="1">membrane; Receptor/Transporter</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>The three downregulated proteins are marked with (<sup>&#x0002a;</sup>). All other (n&#x0200a;=&#x0200a;8) proteins were either expressed exclusively in HIV-infected cells or were upregulated compared to those detected in the uninfected cells. Protein names, abbreviations, locations and accession numbers are according to SwissProt. Putative functions and significance scores in relation to lipid metabolism were calculated by Fisher Exact Test using software from Ingenuity Systems Inc. A p-value of &#x0003c;0.05 represents a statistically significant non-random association of a specific protein with a lipid-related function/s in the Global Functional Analysis</p></fn></table-wrap-foot></table-wrap><p>More than 66&#x00025; (12 of 18) of the identified proteins were detected exclusively in HIV-infected cells (i.e. produced <italic>de novo</italic> after HIV infection). These proteins were not detected in the counterpart uninfected cells tested at different phases of cell growth or at each of the 14 time points over a period of &#x0003e;3 months (<xref ref-type="fig" rid="pone-0003003-g002">Figures 2</xref>). Two of the existing proteins were upregulated and four proteins were downregulated post-infection (<xref ref-type="fig" rid="pone-0003003-g003">Figure 3</xref>).</p><fig id="pone-0003003-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0003003.g002</object-id><label>Figure 2</label><caption><title>Proteins detected exclusively in HIV-infected cells by MALDI-TOF mass spectrometry from multiple gels.</title><p>These proteins were not detected in counterpart uninfected cells tested at multiple time points and various stages of cell growth. X-axis&#x0200a;=&#x0200a;protein names (abbreviations) are according to SwissPROT: Y-axis&#x0200a;=&#x0200a;average of normalized quantity and standard deviations for each protein expressed in multiple gels. The line limits are &#x0002b;/&#x02212; one standard deviation for the range of data points for each protein. Full protein names and Accession #s of each protein are provided in <xref ref-type="table" rid="pone-0003003-t001">Table 1</xref>.</p></caption><graphic xlink:href="pone.0003003.g002"/></fig><fig id="pone-0003003-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0003003.g003</object-id><label>Figure 3</label><caption><title>Proteins modulated by HIV post-infection.</title><p>Up-regulated proteins are APOB and LRP1 and downregulated proteins are ACBP, STIP1, LRP2, and PDIA3. X-axis&#x0200a;=&#x0200a;protein names (abbreviations according to SwissPROT). Each protein was detected in multiple gels. Y-Axis&#x0200a;=&#x0200a;average of normalized quantities and standard deviations for each protein detected in multiple gels. The line limits are &#x0002b;/&#x02212; one standard deviation for the range of data points for each protein. Full protein names and Accession #s of each protein are provided in <xref ref-type="table" rid="pone-0003003-t001">Tables 1</xref> &#x00026; <xref ref-type="table" rid="pone-0003003-t002">2</xref>.</p></caption><graphic xlink:href="pone.0003003.g003"/></fig><p>A functional categorization of each protein indicated that seven proteins belonged to various families of enzymes/kinases; five were transporter proteins, two transmembrane receptors, two molecular chaperones, and one each of the ligand-binding and adapter-like proteins (<xref ref-type="table" rid="pone-0003003-t001">Tables 1</xref>&#x00026; <xref ref-type="table" rid="pone-0003003-t002">2</xref>). The precursors of most of the secretory proteins could be located in the cytoplasm or cytoskeleton.</p><p>Herein, we demonstrate that each of the differentially regulated proteins (scripted in bold), is biologically relevant and has been shown to play statistically significant role/s in cellular functions associated with lipid metabolism.</p></sec><sec id="s2b"><title>2. Enzymes and Proteins Involved in Enhanced Fatty Acid Synthesis</title><p>One of the most essential biological processes involved in dyslipidemia and lipodystrophy syndrome is the accumulation of lipids and disproportionate distribution of <italic>tissue-associated</italic> fats due to the enhanced fatty acid synthesis. Since kinases and enzymes activate most cellular functions including lipid synthesis, we first analyzed the functional significance of these proteins in HIV-infected cells in comparison with those expressed in the uninfected control cells.</p><p>Of the 18 differentially expressed proteins in HIV-infected cells, six enzymes/kinases were expressed exclusively in HIV-infected cells (CO3, P3C2B, KPCB, FAS, ACSL1, and GPX1) and one isomerase (PDIA3) was slightly downregulated after chronic HIV infection (<xref ref-type="table" rid="pone-0003003-t001">Table 1</xref>&#x00026; <xref ref-type="fig" rid="pone-0003003-g003">Figure 3</xref>). All of these enzymes/ peptidase/kinases have been shown to be essential for the fatty acid synthesis as well as for numerous molecular interactions necessary for lipid metabolism (<xref ref-type="table" rid="pone-0003003-t001">Table 1</xref>). None of these enzymes was detected in any of the corresponding gel-spots tested from the uninfected cells over a long period of growth (<xref ref-type="table" rid="pone-0003003-t001">Table 1</xref> &#x00026; <xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref>).</p><p>
<bold>The complement C3 peptidase, or CO3 protein</bold> was expressed exclusively in HIV-infected cells. This extracellular membrane bound peptidase was not detected in any of the numerous uninfected counterpart cells tested (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref>). The complement cascade is probably activated by HIV infection since C3- binding domains are present on HIV envelope gp120 as well as gp41 sequences <xref rid="pone.0003003-Stoiber1" ref-type="bibr">[60]</xref>. This increases the rate of infection in different cell types of the body and contributes to HIV pathogenesis <xref rid="pone.0003003-Stoiber2" ref-type="bibr">[61]</xref>, <xref rid="pone.0003003-Susal1" ref-type="bibr">[62]</xref>. Another important characteristic of the CO3 interaction with HIV is due to the sequence identity of the C3- activation peptide to an acylation-stimulating lipogenic protein produced by adipocytes <xref rid="pone.0003003-Murray1" ref-type="bibr">[36]</xref>, <xref rid="pone.0003003-Wetsel1" ref-type="bibr">[63]</xref>. Since C3 is a primary contact point with HIV envelope and other cell surface proteins, the lipogenic process is most likely initiated very early in HIV infected cells (SR unpublished data). During lipogenesis, glucose is converted to fatty acids, which are subsequently esterified to glycerol to form triacylglycerols <xref rid="pone.0003003-Ducharme1" ref-type="bibr">[64]</xref>. In the rat model system, elevated levels of CO3 were shown to be critical for <italic>de novo</italic> lipogenesis and these have been associated with liver lipodystrophy observed during myo-inositol deficiency <xref rid="pone.0003003-Beach1" ref-type="bibr">[65]</xref>, <xref rid="pone.0003003-Moon1" ref-type="bibr">[66]</xref>. It is also noteworthy that high levels of CO3 protein in <italic>non-HIV infected</italic> individuals have been associated with higher lipid production, high blood pressure and risk of cardiovascular disease <xref rid="pone.0003003-Engstrom1" ref-type="bibr">[67]</xref>, <xref rid="pone.0003003-Ajjan1" ref-type="bibr">[68]</xref>. Our functional bioinformatics analyses identified CO3 protein to be significantly associated with lipid-related proteins and therefore may increase the quantity of free fatty acids (p&#x0200a;=&#x0200a;0.005). Additionally, CO3 is also involved in the removal and clearance of triacylglycerol (p&#x0200a;=&#x0200a;0.0002) (<xref ref-type="table" rid="pone-0003003-t001">Table 1</xref>&#x00026; <xref ref-type="fig" rid="pone-0003003-g001">Figures 1</xref>&#x00026; <xref ref-type="fig" rid="pone-0003003-g002">2</xref>).</p><p>While the HIV-infected cells showed <italic>de novo</italic> expression of <bold>phosphatidylinositol-4-phosphate 3-kinase C2</bold>
<bold>domain-containing beta polypeptide</bold> (<bold>P3C2B or PI3K,</bold>
<italic>)</italic> at several time points, the uninfected T-cells did not (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref> &#x00026; <xref ref-type="table" rid="pone-0003003-t001">Table 1</xref>). This membrane-bound enzyme is a major lipid messenger that may be activated soon after binding of the viral envelope to the plasma membrane <xref rid="pone.0003003-Pendaries1" ref-type="bibr">[69]</xref>. In the initial phases of virus replication this kinase is involved in both receptor-mediated responses and intracellular signaling that are critical for cell survival and virus spread <xref rid="pone.0003003-Pendaries1" ref-type="bibr">[69]</xref>, <xref rid="pone.0003003-Anderson1" ref-type="bibr">[70]</xref>. This enzyme has been localized to the cytoplasmic lipid bodies, which mediate signals in lymphocytes and monocytes <xref rid="pone.0003003-Yu1" ref-type="bibr">[71]</xref>. Furthermore, the expression of PI3K in mice with knockout phosphatidylinositol 5-phosphate 4-kinase (beta) gene was correlated with hypersensitivity to insulin <xref rid="pone.0003003-Lamia1" ref-type="bibr">[72]</xref>. These animals showed significantly less body fat compared to the wild-type mice indicating that PI3 kinase is essential for the lipid synthesis <xref rid="pone.0003003-Lamia1" ref-type="bibr">[72]</xref>. It is also notable that Nelfinavir, a protease inhibitor, can induce a defect in the insulin signaling cascade <italic>downstream</italic> of the activation of PI3-kinase <italic>in vitro</italic>
<xref rid="pone.0003003-BenRomano1" ref-type="bibr">[17]</xref>. These results suggest that HIV- induced enzymes can be further modulated by antiviral treatments. Our bioinformatics analysis indicated that the signaling activities of PI3K /P3C2B kinase are essential for lipid synthesis and adiposity (p&#x0200a;=&#x0200a;0.02).</p><p>One of the most critical enzymes for the synthesis of fatty acids is the <bold>fatty acid synthase</bold>
<bold>(FAS</bold>
<bold><italic>)</italic></bold>. This enzyme was detected only in HIV-infected cells and was not expressed in the uninfected counterpart T-cells (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref>). Recently another proteomics study reported upregulation of FAS after HIV infection and associated this enzyme to the dysregulation of the cell cycle post-HIV infection <xref rid="pone.0003003-Chan1" ref-type="bibr">[56]</xref>. FAS has multiple domains of interactions that catalyze the formation of long-chain fatty acids and is therefore a key lipogenic enzyme in catalyzing the terminal steps in the <italic>de novo</italic> biogenesis of fatty acids <xref rid="pone.0003003-Beach1" ref-type="bibr">[65]</xref>, <xref rid="pone.0003003-Moon1" ref-type="bibr">[66]</xref>. An increase of FAS has been associated with liver lipodystrophy and production of this enzyme was suppressed by polyunsaturated fatty acids, signifying its role in lipid synthesis and production of fatty acids <xref rid="pone.0003003-Beach1" ref-type="bibr">[65]</xref>, <xref rid="pone.0003003-Moon1" ref-type="bibr">[66]</xref>. Our bioinformatics analysis also indicated that FAS is significantly associated with <italic>de novo</italic> lipogenesis and enhances the synthesis of myristate and stearic acids (p&#x0200a;=&#x0200a;0.02).</p><p>A multifunctional enzyme <bold>glutathione peroxidase-1 (GPX1or GSHC)</bold> was expressed in HIV-infected cells but it was not detected in the counterpart uninfected cells (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref>). This enzyme has antioxidant properties and it protects cells (and the body) against the lethal oxidative stress <xref rid="pone.0003003-Cheng1" ref-type="bibr">[73]</xref>. Elevated levels of GPX1 have been reported in HIV-infected adolescent and young adults with or without antiretroviral drug treatments, both of which cause oxidative stress <xref rid="pone.0003003-Stephensen1" ref-type="bibr">[74]</xref>. In an unrelated study, cells transfected with HIV <italic>env</italic> genes showed a 100&#x00025; increase in GPX expression <xref rid="pone.0003003-Zhao1" ref-type="bibr">[75]</xref>. Deficiency or inactivation of GPX1 has been associated with diabetic macrovascular disease, reduced mitochondrial energy production and increased oxidative stress, indicating its protective role <italic>in vivo</italic>
<xref rid="pone.0003003-Cheng1" ref-type="bibr">[73]</xref>, <xref rid="pone.0003003-Lewis1" ref-type="bibr">[76]</xref>. These characteristics may also be critical for maintaining cellular integrity during virus replication (SR unpublished observations). An important property of GPX1 related to lipid metabolism is that the quantity of this protein correlates with the production of malondialdehyde, a major endogenous lipid peroxidation product that has been considered as a marker of oxidative damage (SR unpublished observations) <xref rid="pone.0003003-Cheng1" ref-type="bibr">[73]</xref>, <xref rid="pone.0003003-Feng1" ref-type="bibr">[77]</xref>. Overexpression of GPX1 has also been reported to disrupt insulin functions by quenching intracellular reactive oxygen species required for insulin sensitivity <xref rid="pone.0003003-McClung1" ref-type="bibr">[78]</xref>. By the use of Ingenuity Systems' bioinformatics programs, GPX1 was found to be significantly associated with enhanced quantity of fatty acids (p&#x0200a;=&#x0200a;0.01)(<xref ref-type="table" rid="pone-0003003-t001">Table 1</xref>).</p><p>Among the seven <italic>de novo</italic> synthesized enzymes in HIV-infected cells, <bold>protein kinase C, beta type (KPCB or PKC)</bold> showed the highest peak of expression with a significance score of p&#x0200a;=&#x0200a;0.02 in relation to the synthesis and metabolism of lipids in humans (<xref ref-type="table" rid="pone-0003003-t001">Table 1</xref>; <xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref>). PKC is a phospholipid-dependent serine-threonine kinase, which regulates the production of phosphatidylethanolamine <xref rid="pone.0003003-BenRomano1" ref-type="bibr">[17]</xref>, <xref rid="pone.0003003-Shih1" ref-type="bibr">[79]</xref>, <xref rid="pone.0003003-Wakasaki1" ref-type="bibr">[80]</xref>. Among the many cellular functions associated with the expression of KPCB /PKC, the synthesis and secretion of lipids by epithelial cells appear to be most relevant to our research goals <xref rid="pone.0003003-Rohlfs1" ref-type="bibr">[81]</xref>. Overexpression of this kinase has also been shown to cause functional changes that lead to hyperglycemia, lipid-associated diabetic vascular complications, and cardiomyopathy in humans <xref rid="pone.0003003-Wakasaki1" ref-type="bibr">[80]</xref>, <xref rid="pone.0003003-Way1" ref-type="bibr">[82]</xref>. Upregulation of KPCB /PKC in eosinophils has been linked to the formation of non-nuclear lipid bodies and induction of platelet-activating factor (PAF), which increases the synthesis of eicosanoids (polyunsaturated fatty acids or arachidonic acids) <xref rid="pone.0003003-Bozza1" ref-type="bibr">[83]</xref>. These data provide overwhelming evidence that activation of PKC enzyme is essential for lipid metabolism <xref rid="pone.0003003-Way1" ref-type="bibr">[82]</xref>.</p><p>An interesting observation of our study was that the <bold>long-chain-fatty-acid-CoA ligase 1</bold>
<bold>(ACSL1: synonym,</bold>
<bold>acyl-CoA synthetase</bold>
<bold><italic>)</italic></bold> was detected within 1.5 hrs after HIV infection, while most other differentially expressed proteins were not quantifiable at this time. This enzyme was induced <italic>de novo</italic> after HIV infection of T-cells <italic>in vitro</italic> and was not detected in any of the numerous gels from the uninfected counterpart cells (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref>). The lipogenic activity of this enzyme is also essential for fatty acid metabolism in various tissues as it provides activated intermediates for complex lipid synthesis, protein modification and beta-oxidation <xref rid="pone.0003003-Parkes1" ref-type="bibr">[84]</xref>, <xref rid="pone.0003003-Tong1" ref-type="bibr">[85]</xref>. Our statistical and bioinformatics analyses identify ACSL1 to be critical for increased quantities of fatty acids (p&#x0200a;=&#x0200a;0.02) and storage of fatty acids as triglycerides (p&#x0200a;=&#x0200a;0.005) (<xref ref-type="table" rid="pone-0003003-t001">Table 1</xref>).</p><p>The <bold>fatty acid binding protein epidermal (FABP5 or FABPE</bold>) protein was expressed exclusively in the experimentally HIV-infected T-cells (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref>; <xref ref-type="table" rid="pone-0003003-t002">Table 2</xref>). Although a recent proteomics study reported FABPE to be slightly downregulated after HIV infection <xref rid="pone.0003003-Ringrose1" ref-type="bibr">[57]</xref>, we did not detect this protein in multiple gels of uninfected cells tested at various stages of cell growth and replication. This may be due to differences in the host cells (C33A cervical carcinoma and PML cells) and the virus (HIV-LAI) used in that study <xref rid="pone.0003003-Ringrose1" ref-type="bibr">[57]</xref>. However, in normal physiological conditions, FABP5 is expressed during differentiation of human skin, heart, intestine and adipose tissues <xref rid="pone.0003003-Siegenthaler1" ref-type="bibr">[86]</xref>. Since FABP5 binds to fatty acids with high specificity, there is a breakdown in the storage of fats during lipolysis, resulting in the release of free fatty acids into the bloodstream <xref rid="pone.0003003-Hertzel1" ref-type="bibr">[87]</xref>. An increase in the expression levels of FABP5 after HIV infection of T-cells <italic>in vitro</italic> suggests its role in producing free fatty acids at a higher rate in these cells (p&#x0200a;=&#x0200a;0.02) (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref> &#x00026;<xref ref-type="table" rid="pone-0003003-t002">Table 2</xref>).</p></sec><sec id="s2c"><title>3. Overexpression of Low Density Lipoproteins and their Receptors</title><p>Our proteomics analyses indicated that the <bold>low-density lipoprotein (LDL) receptor 1 (LRP1)</bold> was excessively upregulated post-HIV infection with 148&#x00025; higher quantity than detected in the uninfected control cells (<xref ref-type="table" rid="pone-0003003-t002">Table 2</xref> and <xref ref-type="fig" rid="pone-0003003-g003">Figures 3</xref>). This receptor is one of the most important regulators of lipid metabolism and is involved in cell signaling, transportation, and aggregation of lipids through a wide range of mechanisms <xref rid="pone.0003003-LlorenteCortes1" ref-type="bibr">[88]</xref>&#x02013;<xref rid="pone.0003003-Chappell1" ref-type="bibr">[90]</xref>. Unlike the high affinity LDL receptors that bind to LDL particles and internalize them for degradation and clearance, LRP1 binds to multiple ligands but more specifically to <italic>aggregated</italic> LDL (AgLDL) <xref rid="pone.0003003-LlorenteCortes1" ref-type="bibr">[88]</xref>, <xref rid="pone.0003003-CaminoLopez1" ref-type="bibr">[91]</xref>. Since LRP1 is the receptor for AgLDL, it plays a significant role in altering signal transduction pathways, and this property distinguishes LRP1 from &#x0201c;classical&#x0201d; LDL receptors <xref rid="pone.0003003-LlorenteCortes2" ref-type="bibr">[92]</xref>. The aggregated AgLDL particles provoke accumulation of cholesteryl esters and modulate adipocyte differentiation-related proteins on the surface of lipid droplets <xref rid="pone.0003003-LlorenteCortes2" ref-type="bibr">[92]</xref>. Interaction of LRPs with cell surface proteoglycans <italic>in vitro</italic> has been shown to induce catabolism of triglyceride-rich lipoproteins <xref rid="pone.0003003-CaminoLopez1" ref-type="bibr">[91]</xref>. Increased expression of LRP1 is also positively associated with increased quantity of <italic>free</italic> fatty acids <xref rid="pone.0003003-Chappell1" ref-type="bibr">[90]</xref>. LRP1 is normally associated with macrophages and vascular smooth muscle cells and is upregulated in lipid-enriched plaques in atherosclerotic lesions <xref rid="pone.0003003-LlorenteCortes1" ref-type="bibr">[88]</xref>, <xref rid="pone.0003003-LlorenteCortes2" ref-type="bibr">[92]</xref>, <xref rid="pone.0003003-LlorenteCortes3" ref-type="bibr">[93]</xref>. In addition, lipid peroxidation of low and very low density lipoproteins has been implicated in early stages of heart diseases through multiple potential pathways <xref rid="pone.0003003-EspiritoSanto1" ref-type="bibr">[94]</xref>, <xref rid="pone.0003003-Xu2" ref-type="bibr">[95]</xref>. Overexpression of LRP1 in our experimentally HIV infected cells exemplifies its multiple roles in enhancing the quantity of fatty acids (p&#x0200a;=&#x0200a;0.02), increasing free fatty acids (p&#x0200a;=&#x0200a;0.005), removal of lipids (p&#x0200a;=&#x0200a;0.0002) and clearance of triacylglcerol (p&#x0200a;=&#x0200a;0.0005) (<xref ref-type="table" rid="pone-0003003-t002">Table 2</xref>).</p><p>In addition to LRP1, the HIV infected cells expressed <bold>the Very Low-Density Lipoprotein Receptors (VLDLR</bold>'<bold>s</bold>
<bold><italic>)</italic></bold>. These receptors were not expressed in any of the uninfected cells at different phases of growth (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref> &#x00026; <xref ref-type="table" rid="pone-0003003-t002">Table 2</xref>). Bioinformatics analysis indicated that the expression of VLDLR's is highly significant in increasing the quantity of fatty acids and triglycerides/free fatty acids (p&#x0200a;=&#x0200a;0.01 &#x00026; p&#x0200a;=&#x0200a;0.005 respectively). In addition these receptors are essential for the transport and depletion of lipids (p&#x0200a;=&#x0200a;0.0002) and clearance of triacylglycerol (p&#x0200a;=&#x0200a;0.0005). The VLDLR's bind to very low density lipoproteins and mediate their catabolism <italic>in vitro</italic>
<xref rid="pone.0003003-Domingo1" ref-type="bibr">[96]</xref>. Thus, expression of both VLDLR's and LRP1 would not only be expected to increase the quantities of LDL and VLDL, but would also reduce clearance rates of very low density lipoproteins into denser particles in both treatment-na&#x000ef;ve and anti-retroviral treated individuals <xref rid="pone.0003003-Das1" ref-type="bibr">[97]</xref>&#x02013;<xref rid="pone.0003003-Shelness1" ref-type="bibr">[99]</xref>. This is a major cause of lipodystrophy in HIV-infected individuals regardless of treatments <xref rid="pone.0003003-Das1" ref-type="bibr">[97]</xref>, <xref rid="pone.0003003-Shahmanesh1" ref-type="bibr">[100]</xref>, <xref rid="pone.0003003-Carpentier1" ref-type="bibr">[101]</xref>.</p><p>Among all the differentially regulated proteins the <bold>Apolipoprotein-B100 (APOB)</bold> showed the highest quantity with a 1327&#x00025; increase after HIV infection compared to the minimum detectable levels present in uninfected (control) cells (<xref ref-type="fig" rid="pone-0003003-g003">Figure 3</xref>). The APOB is associated with the low density lipoproteins (LDL), intermediate density lipoproteins (IDL), and very low density lipoproteins (VLDL) particles. In both treated and untreated HIV patients, the APOB, VLDL and IDL have been associated with fractional clearance rates <xref rid="pone.0003003-Das1" ref-type="bibr">[97]</xref>, <xref rid="pone.0003003-MacDougall1" ref-type="bibr">[98]</xref>, <xref rid="pone.0003003-Packard1" ref-type="bibr">[102]</xref>. Expression of APOB is clinically significant as it assembles atherogenic lipoproteins involved in plaque formation <xref rid="pone.0003003-Olofsson1" ref-type="bibr">[103]</xref>. Functional bioinformatics analysis indicated that APOB enhances the quantity of both the cell-associated and cell-free fatty acids (p&#x0200a;=&#x0200a;0.01 &#x00026; p&#x0200a;=&#x0200a;0.005 respectively). In addition, this protein increases secretion and mobilization of various cholesterols (triacylglycerols) in cooperation with apolipoprotein A1 (p&#x0200a;=&#x0200a;0.01). <italic>In vitro</italic> studies have also indicated that the lipidation of APOB results in the conversion of LDL <italic>from</italic> HDL <italic>to</italic> VLDL <xref rid="pone.0003003-Yamaguchi1" ref-type="bibr">[104]</xref>. An increase in LDL subclass B has also been associated with perturbation of lipid metabolism and dysregulation of triglycerides in patients with AIDS suggesting its role in progression of cholesterol-associated metabolic abnormalities <xref rid="pone.0003003-Feingold1" ref-type="bibr">[105]</xref>.</p><p>In HIV-infected cells <bold>apolipoprotein-A1 (APOA1</bold>
<bold><italic>)</italic></bold> was synthesized <italic>de novo</italic> post-HIV infection and it was not detected in any of the multiple samples tested from the uninfected counterpart cells (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref> &#x00026; <xref ref-type="table" rid="pone-0003003-t002">Table 2</xref>). Although, APOA1 has been considered as a major protein component associated with high density lipoprotein (HDL) or &#x0201c;good&#x0201d; cholesterol <xref rid="pone.0003003-Leroy1" ref-type="bibr">[106]</xref>, our bioinformatics analyses using Ingenuity's Global Functional Analysis programs indicate that APOA1 is one of the most active proteins that performs multiple functions in lipid metabolism, all of which are statistically significant p-value (p&#x0200a;=&#x0200a;0.02) (<xref ref-type="fig" rid="pone-0003003-g001">Figure 1</xref>). For example, APOA1 by itself is sufficient for recruitment of cholesterol and sphingomyelin; depletion of phosphatidylcholine; mobilization and translocation of cholesterol; secretion of lysophosphatidylcholine and cholesterols. In cooperation with LRP1, APOA1 helps in the transport of cholesterol esters (p&#x0200a;=&#x0200a;0.002). Coordinated expression of APOA1 with C3 (CO3), LRP1, and VLDLR in HIV infected cells is highly significant in the removal of lipids (p&#x0200a;=&#x0200a;0.0002). All of these proteins (LRP1, C3 and VLDLR) were co-expressed and excessively upregulated in our experimentally HIV infected cells suggesting their functional interactions (<xref ref-type="table" rid="pone-0003003-t001">Table 1</xref> and <xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref>). The activated APOA1 also has a proteolytic enzyme activity which is capable of degrading APOB-100 into smaller fragments <xref rid="pone.0003003-Chulkova1" ref-type="bibr">[107]</xref>. Thus, an amphipathic peptide analogue of APOA1 has been reported to inhibit cell fusion in both herpes simplex virus (HSV) and HIV infected cells <xref rid="pone.0003003-Srinivas1" ref-type="bibr">[108]</xref>, <xref rid="pone.0003003-Panin1" ref-type="bibr">[109]</xref>. Specific subclasses of APOA1 have also been effective in enhancing cholesterol efflux from cells in various phases of reverse cholesterol transport <xref rid="pone.0003003-Leroy1" ref-type="bibr">[106]</xref>.</p><p>In an unrelated proteomics-based study, detection of APOA1 in the plasma of HIV-infected individuals was considered a &#x0201c;biomarker for HIV diagnosis&#x0201d; in patients with AIDS. The &#x0201c;diagnostic&#x0201d; significance of APOA1 needs to be further studied as these patients had AIDS and some were on HAART for 2 months <xref rid="pone.0003003-Kim1" ref-type="bibr">[110]</xref>. However, it is evident that APOA1 is synthesized <italic>de novo</italic> in the experimentally HIV infected cells without any influence of additional factors. These data indicate that the biological functions of this protein are more versatile than previously envisioned and the multiple roles played by APOA1 in different aspects of lipid metabolism are highly significant (p&#x0200a;=&#x0200a;0.0001 to 0.02).</p></sec><sec id="s2d"><title>4. Lipid Oxidation and Crystallization</title><p>An unexpected finding of our proteomics study was that significant amounts of <bold>albumin (ALBU)</bold> precursor protein were synthesized <italic>de novo</italic> in HIV-infected cells i.e. not detected in any of the uninfected counterpart cells in wide range of growth phases over a period of &#x0003e;3 months (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref>). Albumin is a major multifunctional secretory/transporter protein that binds to hormones, bilirubin, drugs, a variety of elements Ca (2&#x0002b;), Na (&#x0002b;), K (&#x0002b;) and other molecules present in the plasma <xref rid="pone.0003003-Curry1" ref-type="bibr">[111]</xref>. The human ALBU also binds to fatty acids with high affinity as it has several polymorphic forms with long hydrophobic pockets that are distributed asymmetrically throughout the repeating domains of this protein <xref rid="pone.0003003-Curry1" ref-type="bibr">[111]</xref>, <xref rid="pone.0003003-Fujiwara1" ref-type="bibr">[112]</xref>. The binding of ALBU to fatty acids regulates enzymes that metabolize, esterify and crystallize lipids <xref rid="pone.0003003-Dadaian1" ref-type="bibr">[113]</xref>. The upregulation of ALBU, a &#x0201c;normal&#x0201d; protein is therefore highly significant (p&#x0200a;=&#x0200a;0.02) as it plays a significant role in crystallization of cholesterol. The high affinity binding of fatty acids to ALBU <italic>in vivo</italic>, also results in excessive secretion of APOB, leaving fatty acids unavailable for lipoprotein assembly in hepatocytes <xref rid="pone.0003003-Ha1" ref-type="bibr">[114]</xref>. The HIV-infected individuals who show higher LDL levels in the plasma also have albuminaemia indicating coordinated upregulation of ALBU with increased lipid profiles <xref rid="pone.0003003-Constans1" ref-type="bibr">[5]</xref>. In the present study expression of lipogenic proteins correlated with the expression of ALBU in HIV-infected cells (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref> &#x00026; <xref ref-type="table" rid="pone-0003003-t002">Table 2</xref>). Another most relevant finding related to our experimental results was that binding of ALBU to the complement C3 protein results in the formation of microbubbles that adhere to vascular endothelium and accelerate atherosclerotic processes <xref rid="pone.0003003-Anderson2" ref-type="bibr">[115]</xref>. As noted earlier, both ALBU and the C3 proteins were expressed only in HIV-infected cells and these proteins were not detected in uninfected cells, suggesting their putative co-operative roles in inducing lipid abnormalities (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref>).</p></sec><sec id="s2e"><title>5. Effects of Downregulated Proteins on Lipid Metabolism</title><p>The differential proteomics analyses of HIV-infected and uninfected cells identified four proteins (<bold>ACBP, PDIA3, STIP1 &#x00026; LRP2</bold>) that were downregulated post-HIV-infection (<xref ref-type="fig" rid="pone-0003003-g003">Figure 3</xref>). Functional bioinformatics analyses indicated that suppression of these proteins could be associated with increased production of proteins that enhance lipid synthesis and quantity (<xref ref-type="fig" rid="pone-0003003-g001">Figure 1</xref>). For example, <bold>Acyl-CoA binding protein</bold>
<bold>(ACBP</bold>
<bold><italic>)</italic></bold> is a key protein that modulates the long- chain fatty acyl-coenzyme-A (Acyl-CoA) metabolism <xref rid="pone.0003003-Huang1" ref-type="bibr">[116]</xref>. This protein is normally induced during adipocyte differentiation and its downregulation inhibits adipocyte differentiation which results in growth arrest and adipocyte cell death <xref rid="pone.0003003-Mandrup1" ref-type="bibr">[117]</xref>. The slight decrease in the expression of ACBP in HIV infected cells (<xref ref-type="fig" rid="pone-0003003-g003">Figure 3</xref>) suggests that downregulation of this protein may be potentially harmful for adipocyte differentiation <italic>in vivo</italic>. ACBP also facilitates esterification of long-chain fatty acids with coenzyme (Acyl-CoA) which is the first step in fatty acid metabolism <xref rid="pone.0003003-Huang1" ref-type="bibr">[116]</xref>. Depletion of this protein in cells has been shown to result in abnormalities of lipid metabolism, particularly those involved in fatty acyl-CoA long chain formation <xref rid="pone.0003003-Huang1" ref-type="bibr">[116]</xref>, <xref rid="pone.0003003-Lee1" ref-type="bibr">[118]</xref>. Loss of ACBP also leads to triacylglycerol biosynthesis abnormalities as it binds long-chain fatty acyl-CoA esters and facilitates its transportation <xref rid="pone.0003003-Lee1" ref-type="bibr">[118]</xref>, <xref rid="pone.0003003-Lamberg1" ref-type="bibr">[119]</xref>. The downregulation of ACBP therefore significantly enhances abnormalities and mobilization of triglycerides (p&#x0200a;=&#x0200a;0.02).</p><p>The quantity of <bold>protein disulphide isomerase (PDIA3),</bold> previously known as <bold>phosphoinositol-specific phospholipase C</bold> was about 9&#x00025; lower in HIV-infected cells than the uninfected cells (i.e.downregulated) (<xref ref-type="fig" rid="pone-0003003-g003">Figure 3</xref>). Although in another study, PDIA3A was shown to be upregulated 2.43-fold after 42 hours of &#x0201c;massive&#x0201d; (high multiplicity of HIV infection), this may be due to variations in the HIV strain (LAI clone) used for this study, the macrophage tropism of the virus, the cells used to grow the virus ( C33A human cervical carcinoma monolayer cells and PM1 T cells) <xref rid="pone.0003003-Ringrose1" ref-type="bibr">[57]</xref>, <xref rid="pone.0003003-Peden1" ref-type="bibr">[120]</xref>. While the expresssion of PDIA3A was initially reported to be important in the reproductive tract and placenta <xref rid="pone.0003003-CharnockJones1" ref-type="bibr">[121]</xref>, this peptidase is shown to be critical for disulfide bond formation of newly synthesized proteins <xref rid="pone.0003003-Lamberg1" ref-type="bibr">[119]</xref>, <xref rid="pone.0003003-Burch1" ref-type="bibr">[122]</xref>. PDIA3 also plays an important role in signal transduction from the cell surface receptor to other parts of the cells including the nucleus and endoplasmic reticulum <xref rid="pone.0003003-CharnockJones1" ref-type="bibr">[121]</xref>. This protein is identical to the beta subunit of the microsomal triacylglycerol transfer protein (MTP), which is a multifunctional protein essential for the assembly, folding, and secretion of APOB-containing lipoproteins <xref rid="pone.0003003-Lamberg1" ref-type="bibr">[119]</xref>, <xref rid="pone.0003003-Burch1" ref-type="bibr">[122]</xref>, <xref rid="pone.0003003-Rehberg1" ref-type="bibr">[123]</xref>. The absence or downregulation of the beta subunit may cause defective secretion of APOB-containing lipoproteins, which would then promote development of beta-lipoproteinemia, an autosomal recessive disease <xref rid="pone.0003003-Burch1" ref-type="bibr">[122]</xref>, <xref rid="pone.0003003-Rehberg1" ref-type="bibr">[123]</xref>. During lipid metabolism, PDIA3A is also significantly associated with the cleavage of phosphatidylinositol (p&#x0200a;=&#x0200a;0.02).</p><p>The <bold>stress-induced-phosphoprotein 1 (STIP1</bold>
<bold><italic>)</italic></bold> was downregulated post-HIV infection (<xref ref-type="fig" rid="pone-0003003-g003">Figure 3</xref>). This is a co-chaperone or an adapter for the human <bold>heat shock proteins (HSPs)</bold>
<bold>Hsp70/Hsp90 (or HS7H and HS9B)</bold> machinery which organizes complex interactions with other proteins <xref rid="pone.0003003-Mizrak1" ref-type="bibr">[124]</xref>, <xref rid="pone.0003003-Longshaw1" ref-type="bibr">[125]</xref>. Both HS7H and HS9B were <italic>upregulated</italic> exclusively in HIV-infected T-cells and were not expressed in uninfected cells (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref>; <xref ref-type="table" rid="pone-0003003-t002">Table 2</xref>). In general these proteins are expressed in response to the endogenous stress and they protect cells from injury (i.e. inhibit apoptosis) <xref rid="pone.0003003-Gao1" ref-type="bibr">[126]</xref>, <xref rid="pone.0003003-Hashiguchi1" ref-type="bibr">[127]</xref>. In physiologic conditions, coordinated expression of HS7H and HS9B stabilizes preexisting proteins against aggregate formation and they mediate correct folding and maturation of newly synthesized cellular proteins <xref rid="pone.0003003-Gao1" ref-type="bibr">[126]</xref>, <xref rid="pone.0003003-Chen1" ref-type="bibr">[128]</xref>, <xref rid="pone.0003003-Smith1" ref-type="bibr">[129]</xref>. During the assembly of multicomponent complexes, HS7H and HS9B alter conformations of substrate proteins as and when needed for specific signal transductions <xref rid="pone.0003003-Chakraborty1" ref-type="bibr">[130]</xref>. HS7H and HS9B are hormone binding proteins and proper assembly of their complexes with progesterone and glucocorticoid receptors depend on the transcriptional activation subsequent to hormone binding <xref rid="pone.0003003-Pratt1" ref-type="bibr">[131]</xref>&#x02013;<xref rid="pone.0003003-Freeman1" ref-type="bibr">[134]</xref>. In an experimental model both progestin and androgen were shown to enhance production of triglycerides particularly after the induction of fatty acid synthetase in cells <xref rid="pone.0003003-Chambon1" ref-type="bibr">[135]</xref>.</p><p>An important and pertinent function relevant to our experimental model is that Hsp70 binds to the activated protein kinase C (PKC) and prolongs the life of the mature kinase by allowing the enzyme to re-phosphorylate <xref rid="pone.0003003-Gao1" ref-type="bibr">[126]</xref>, <xref rid="pone.0003003-Knowlton1" ref-type="bibr">[136]</xref>. As discussed earlier, PKC (KPCB) was overexpressed in HIV infected cells (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref>) and it is an essential enzyme for the generation and regulation of phosphatidylethanolamine that activates diacylglycerol <xref rid="pone.0003003-Way1" ref-type="bibr">[82]</xref>, <xref rid="pone.0003003-Gao1" ref-type="bibr">[126]</xref>, <xref rid="pone.0003003-Knowlton1" ref-type="bibr">[136]</xref>. Any disruption of this interaction would prevent re-phosphorylation of PKC which is essential for multiple functions including fatty acid synthesis. It is therefore not surprising that both HS7H /HS9B complex and PKC were induced <italic>de novo</italic> after HIV infection. The relationship of these proteins to lipid metabolism was scored to be highly significant (p&#x0200a;=&#x0200a;0.0002).</p><p>The <bold>LDL receptor-related protein 2 (LRP2)</bold> was downregulated in HIV-infected cells 3 hrs post- infection (<xref ref-type="fig" rid="pone-0003003-g003">Figure 3</xref> &#x00026; <xref ref-type="table" rid="pone-0003003-t002">Table 2</xref>). This is a multi-ligand receptor (megalin) and it participates in a wide range of physiological functions, including protection against atherosclerosis <xref rid="pone.0003003-May1" ref-type="bibr">[89]</xref>. Downregulation of LRP2 in HIV-infected cells with concomitant upregulation of LRP1 suggests an enhanced production of lipid aggregates and related abnormalities.</p></sec><sec id="s2f"><title>6. Statistical Significance of Protein Interaction Pathways</title><p>All biological processes are regulated by interactions of proteins with other proteins, lipids, lipoproteins, RNA or DNA in order to perform specific cellular functions. Although a complete network of all possible protein-protein interactions in the cell is difficult to visualize, we have constructed protein-interaction pathways of 18 proteins that were identified to be significantly associated with different aspects of lipid metabolism (p-values ranging from 0.0002 to 0.01;<xref ref-type="table" rid="pone-0003003-t001">Tables 1</xref> and <xref ref-type="table" rid="pone-0003003-t002">2</xref>).</p><p>Two different programs were used to construct interaction pathways (Ingenuity Pathway Analysis (IPA) Systems and Strategene Pathway Architect (SPA) software). Although both programs generated conceptually similar pathways, the interaction diagrams presented here were created by Strategene Pathway Architect according to the instructions provided by the manufacturers (<xref ref-type="fig" rid="pone-0003003-g004">Figure 4</xref>).</p><fig id="pone-0003003-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0003003.g004</object-id><label>Figure 4</label><caption><title>Protein-interaction pathways of proteins associated with various aspects of lipid metabolism.</title><p>The functional significance of each protein was defined using Ingenuity bioinformatics platforms designed for Systems Analyses of genes and protein expressed in human health and disease. All proteins were uploaded into the Strategene Pathway Architect (SPA) program and protein-interaction pathways were constructed according to the manufacturer's instructions. Proteins identified by our present proteomics studies are shown with blue outlines; purple-colored proteins are enzymes and kinases and pink-colored (with blue outlines) are other significant proteins involved in the lipid metabolism. Lines connecting proteins indicate molecular networks of interactions. The greater the number of lines originating from a protein, the more significant the molecular interactions of that protein with other protein/s. Note the extensive networks of interactions between all proteins identified in the present study (blue circles), particularly those of APOB and APOA-1. Full protein names, abbreviations and accession numbers of each protein are listed in <xref ref-type="table" rid="pone-0003003-t001">Tables 1</xref>&#x00026;<xref ref-type="table" rid="pone-0003003-t002">2</xref>.</p></caption><graphic xlink:href="pone.0003003.g004"/></fig><p>Using the IPA's bioinformatics programs which integrate the physical, biochemical and biological properties of proteins, we have created tentative scenarios for the 18 proteins whose expression or suppression has been significantly associated with putative steps or functions involved in lipid metabolism (p&#x0200a;=&#x0200a;&#x0003c;0.0002&#x02013;0.01) (<xref ref-type="fig" rid="pone-0003003-g001">Figure 1</xref>). Among the 18 differentially regulated proteins produced in response to HIV infection, FAS, FABPE, KPCB, and P3C2B enzymes/kinases have been shown to be essential for the synthesis and production of fatty acids; the multifunctional molecular chaperon machinery (HS71L/ HS90B) protects PKC kinase and prolongs the life of this enzyme in the cell while preventing other newly synthesized proteins from incorrect folding <xref rid="pone.0003003-Gao1" ref-type="bibr">[126]</xref>. Binding of HS71L/ HS90B proteins to progesterone receptors generates signals for the production of triglyceride in the cell <xref rid="pone.0003003-Chambon1" ref-type="bibr">[135]</xref>. The upregulation of APOB, CO3, LRP1, VLDLR, GPX1, and ACSL1 and slight downregulation of LRP2 have been associated with increased quantities of free fatty acids; the overproduction of APOB and <italic>de novo</italic> synthesis of APOA1 are associated with higher lipid secretion; upregulation and concomitant expression of APOA1, LRP1, VLDLR, and CO3/C3 is critical for lipid depletion, clearance and transport; APOB, together with slightly downregulated ACBP, mobilizes the fatty acids and produces triacylglycerol abnormalities. Production of ALBU esterifies, crystallizes and produces aggregated or oxidized lipids /cholesterols.</p><p>An increased production of APOB-100, VLDLR, and LRP1 in HIV-infected cells also indicates that multiple lipid metabolic pathways are triggered by HIV replication in T-cells. These interactions may induce physiological changes related to lipid metabolism and cholesterol homeostasis, as well as formation of aggregated lipids that bind to LRP1 (<xref ref-type="fig" rid="pone-0003003-g001">Figures 1</xref> &#x00026; <xref ref-type="fig" rid="pone-0003003-g004">4</xref>). As the production of lipid- inducing proteins increases, the numbers of receptors for these ligands are also augmented and new signal transduction molecules are activated. This cascade of events would result in a breakdown of multiple metabolic pathways, especially in HIV-infected individuals.</p></sec><sec id="s2g"><title>7. Antiretroviral Drug does not affect Production of Apolipoproteins</title><p>One of the most significant proteins associated with many lipid related diseases is APOB-100 (p&#x0200a;=&#x0200a;0.01 to 0.005). As indicated earlier, this protein was excessively upregulated in HIV-infected cells post HIV-infection (<xref ref-type="fig" rid="pone-0003003-g003">Figure 3</xref>). Presence of APOB promotes cholesterol efflux and it is absolutely essential for the metabolism of low-density lipoproteins (LDL), the intermediate density lipoproteins (IDL) and the very low-density lipoproteins (VLDL). To validate the sensitivity and specificity of our proteomics technology and the functionality of both viral and cellular proteins, we analyzed the expression of the critical APOB protein in HIV infected, uninfected and counterpart cells treated with an inhibitor and antiviral drug azidothymidine (AZT or Zidovudine). This drug has been shown to inhibit HIV replication <italic>in vitro</italic> and is used in combination with other drugs to treat HIV patients <xref rid="pone.0003003-Wright1" ref-type="bibr">[137]</xref>, <xref rid="pone.0003003-Park3" ref-type="bibr">[138]</xref>. As can be seen in the three sequential gel images of <xref ref-type="fig" rid="pone-0003003-g005">Figure 5</xref>, APOB is NOT inhibited by treatment of HIV-infected cells by Zidovudine while HIV p24, the major gag protein is inhibited. As expected, the HIV-infected cells expressed P24 and the uninfected cells did not. These results not only validate our techniques but also indicate that cellular pathways for the synthesis of APOB are distinct from those of HIV replication (<xref ref-type="fig" rid="pone-0003003-g004">Figures 4</xref> &#x00026; <xref ref-type="fig" rid="pone-0003003-g005">5</xref>).</p><fig id="pone-0003003-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0003003.g005</object-id><label>Figure 5</label><caption><title>Figure 5: Two-dimensional gel electrophoresis patterns of HIV-infected and counterpart uninfected cells T-cells.</title><p>Protein profiles were evaluated 48 hours after treatment with azidothymidine (AZT), or mock treatment with phosphate buffered saline. <xref ref-type="fig" rid="pone-0003003-g005">Figure 5A</xref> represents protein profile of uninfected T-cells and shows theexpression of Apolipoprotein B-100 (APOB) and the absence of HIV p24 antigen. <xref ref-type="fig" rid="pone-0003003-g005">Figure 5B</xref> represents the protein profile of HIV-infected T-cells and displays the presence of both APOB and p24 antigen. <xref ref-type="fig" rid="pone-0003003-g005">Figure 5C</xref> indicates that APOB is NOT inhibited by treatment of HIV-infected cells by AZT while the viral proteins are inhibited by the antiviral drug.</p></caption><graphic xlink:href="pone.0003003.g005"/></fig></sec><sec id="s2h"><title>8. Conclusions</title><p>We conclude that the replication of HIV alone in human T- cells modulates synthesis of novel enzymes, kinases and other proteins that enhance fatty acid synthesis, increase lipid peroxidation (crystallization), disrupt lipid metabolism and reduce lipid clearance. Since HIV-modulated proteins were isolated by a rapid extraction technique and fractionated without the use of any affinity purification techniques such as protein-specific ligands or antibodies, we believe this unbiased proteomics approach has led to the discovery of novel proteins that have not been identified previously in HIV-infected cells.</p><p>Our data provides direct evidence that HIV infection alone can induce a number of novel lipid-associated proteins without any influence of genetic or epigenetic factors that influence metabolic events <italic>in vivo</italic>. Although APOB and VLDL, IDL have been associated with fractional lipid clearance rates in HIV-infected individuals <xref rid="pone.0003003-Das1" ref-type="bibr">[97]</xref>, <xref rid="pone.0003003-MacDougall1" ref-type="bibr">[98]</xref>, <xref rid="pone.0003003-Packard1" ref-type="bibr">[102]</xref>, expression of proteins involved in different aspects of lipid metabolism has not been reported. We have validated our techniques and demonstrated that treatment of HIV-infected cells with antiviral drug Zidovudine does not inhibit the production of APOB, one of the most critical lipid associated proteins while the HIV replication is inhibited (<xref ref-type="fig" rid="pone-0003003-g005">Figure 5</xref>). APOB is a secretory globin-like protein (lipoprotein ) responsible for carrying LDL, which supplies cholesterol to the tissues. Excess lipids are transported through the blood by lipoproteins and are stored in adipocytes. In HIV-infected individuals both protease inhibitors and nucleoside reverse transcriptase inhibitors such as AZT (Zidovudine) have been shown to have detrimental effects on adipose tissue, liver, and muscle <xref rid="pone.0003003-Tanwani1" ref-type="bibr">[6]</xref>, <xref rid="pone.0003003-Leonard1" ref-type="bibr">[7]</xref>, <xref rid="pone.0003003-Carr2" ref-type="bibr">[18]</xref>, <xref rid="pone.0003003-Gomez1" ref-type="bibr">[22]</xref>.</p><p>Bioinformatics and protein- interaction pathway analyses of the 18 differentially regulated proteins indicated that these proteins are biologically relevant as many have been reported in non-HIV infected patients with hyperlipidemia and other lipid-related disorders. <italic>In vivo</italic> the chronically HIV-infected cells produce many secretory cytokines/factors that bind to adipocytes and other cell types (bone marrow, connective tissue, mesenchymal stem cells and others) resulting in enhanced signaling for the production of fatty acids and lipid-regulatory enzymes. Since lipids themselves are excellent signal- transduction molecules, they can bind to cells nonspecifically and induce new signals in both infected and uninfected cells. A cascade of events would then follow before the lipid-related diseases are apparent <italic>in vivo</italic>.</p><p>Translational studies using knockout mice and characterization of the newly discovered proteins by testing the effects of small interfering RNA (RNAi) or small- molecule inhibitors <italic>in vitro</italic> would help in identification of most prevalent, functionally relevant and statistically significant biomarkers for early diagnosis of individuals who might be at high risk for developing lipid-related disorders. Future studies may lead to innovative strategies for developing better therapeutics or inhibitors for preventing lipid-related metabolic disorders.</p><p>This is the first study to experimentally demonstrate correlation between HIV replication and <italic>de novo</italic> expression and/or upregulation of proteins that enhance production of key proteins involved in lipid metabolism.</p></sec></sec><sec id="s3"><title>Materials and Methods</title><p>The primary goal of this study was to apply proteomics-based approaches to study HIV-modulated protein profiles overtime under controlled conditions <italic>in vitro.</italic> The study circumvented problems associated with numerous environmental and genetic factors that influence HIV infection, lipid production and disease progression <italic>in vivo</italic>.</p><sec id="s3a"><title>Cell Cultures and HIV Infection</title><p>To address some of the basic questions related to the virus-host cell interactions, we conducted several labor-intensive proteomics studies to identify proteins modulated by HIV infection alone. Each step of these studies, from sample preparation to data analyses, has been quality- controlled in order to understand the complexities of HIV replication. A T-cell line (RH9) was chosen because HIV replication in these cells is highly efficient and both the HIV and the cell are clonal derivatives. The genome-wide protein profiles solely in response to HIV infection of cells <italic>in vitro</italic> were evaluated without any additional supplements or factors that may possibly influence lipid functions. Cells were grown in RPMI medium containing 10&#x00025; fetal bovine serum and 2mM glutamine with no antibiotics or any cytokine <xref rid="pone.0003003-Rasheed1" ref-type="bibr">[58]</xref>.</p><p>Approximately 6&#x02013;7&#x000d7;10<sup>8</sup> cells were suspended at a concentration of 2&#x000d7;10<sup>6</sup> cells/ml of medium containing 2 ug/ml polybrene. After 24 hrs, one aliquot of 2&#x000d7;10<sup>7</sup> cells was removed as a &#x0201c;baseline control&#x0201d; and remainder of cells were divided equally into two large, 125 cm flasks. One set of cultures was infected <italic>in vitro</italic> with a biological clone of HIV-1(X4 strain) at a multiplicity of infection of one (MOI&#x0200a;=&#x0200a;1) while the counterpart uninfected cells were maintained as the experimental control. Cultures were incubated at 37&#x000b0;C in a humidified atmosphere of 5&#x00025; CO2. After 90 minutes, both sets of cultures were transferred to centrifuge tubes to spin down cells and to remove the medium and /or the virus. All cells were washed once with fresh medium and transferred to new flasks. At this time (i.e. after 1.5 hours), an aliquot of 2&#x000d7;10<sup>7</sup> cells from each culture was removed for analysis and the rest of the cells were incubated as before. Subsequently, both the HIV-infected and uninfected (control) cell samples were collected at multiple time points up to 96 days (i.e. different stages of infection and cell growth at 3 hr, 6 hr, 12 hr, 24 hr, 48 hr, 72 hr, 96 hr, 6 days (d), 10 d, 15 d, 26 d, 47 d and 96 d post-infection . In addition, we tested at least ten different infected and uninfected sets of cells between 10&#x02013;26 days of infection and two separate aliquots grown over a 3 month period from an uncloned culture of the same cell line (H9) that was infected with the X4 HIV strain in 1990's. This culture has been maintained in our laboratory <italic>in vitro</italic> as a chronically infected, virus-productive cell line.</p><p>Supernatants of all cell cultures were harvested for protein analyses, regardless of their time of collection and were tested for the presence of HIV P24 antigen (Abbott's HIV-p24 antigen test).</p></sec><sec id="s3b"><title>Two- Dimensional Gel Electrophoresis (2DGE) and Image Analysis</title><p>Proteins were extracted from approximately 2&#x000d7;10<sup>7</sup> cells from each of the infected and uninfected sets of cultures at each time point using differential extraction procedures established in our lab <xref rid="pone.0003003-Rasheed2" ref-type="bibr">[139]</xref>. Cell pellets were briefly washed twice for 5 minutes each in the phosphate buffered saline (PBS) to remove serum and other pertinacious material, followed by a second wash in Tris (hydroxymethyl)aminomethane. Cells were then solubilized by a sequential two-step procedure using two separate reagent concentrations (5&#x02013;8 M urea, 2&#x02013;4&#x00025; CHAPS, 2 M thiourea and other nonionic and zwitterionic detergents with 2.5&#x00025;carrier ampholytes and protease inhibitor cocktail (BioRad)). The solubilization steps were modified by a rapid lysis technique (10&#x02013;15 seconds followed by 2 seconds' sonication) according to our laboratory's standardized protocols <xref rid="pone.0003003-Rasheed2" ref-type="bibr">[139]</xref>. The first fraction contained the most soluble membrane proteins followed by other membrane, cytoplasmic, and nuclear protein fractions <xref rid="pone.0003003-Rasheed2" ref-type="bibr">[139]</xref>. Each sample was analyzed by isoelectric focusing (IEF), two-dimensional gel electrophoresis (2DGE), image analysis, and Matrix Assisted Laser Desorption Time Of Flight (MALDI- TOF) mass spectrometry as described below.</p><p>For IEF, protein fractions were clarified by centrifugation at 100,000&#x000d7;g, and the supernatant was analyzed in the first dimension on a pH gradient of 3&#x02013;10. Each IEF strip containing separated proteins was then analyzed by 2-dimensional gel electrophoresis (2-DGE) on 6&#x02013;18&#x00025; gradients of SDS-polyacrylamide gels. To analyze low abundant proteins, cell lysates were separated by IEF on different overlapping pH gradients (3&#x02013;10, 4&#x02013;7 and 5&#x02013;8) and then size fractionated by molecular weight using 2DGE on different gradient gels. Each of the HIV-infected and uninfected counterpart samples collected overtime were processed and run at the same time under identical conditions using a 12-gel electrophoresis tank. For quality control, a gel from a lyophilized-reconstituted sample of E. coli proteins was used as a general standard, and one each of the best gels from HIV-infected and counterpart uninfected samples was used as experimental (i.e.HIV-infected and uninfected cells) reference standard with each run.</p><p>Proteins were visualized by staining with Coomassie Blue. Some gels containing proteins of interest were also counterstained with Amido or silver black <italic>after</italic> scanning the images of the Coomassie-stained gels. However, since silver black was not compatible with MS, we used Sypro Ruby red which gave distinctive signals for proteins that were present in both gels but displayed different expression levels. Digitized images of each gel were obtained by CCD camera and protein spots in each of the uninfected and infected samples were analyzed by the use of Melanie and PDQuest softwares. Identical parameters were used for all gel scans including those of the standards and controls against which each image was aligned and matched automatically. Each spot in the uninfected controls was compared with the corresponding spot in gels from the counterpart HIV-infected cells. The software was designed to correct differences in the gel staining according to the algorithms that integrate the optical densities (OD) of each pixel in the spot area and then evaluated normalized quantities against all standardized spot images. Spot intensities were set to differ in the normalized quantities by a factor of 2 compared to the relative average of one group to that of the other. In addition, each gel was critically examined <italic>manually</italic>, and spots matches were corrected if necessary.</p><p>Expression or suppression of many differentially expressed proteins was confirmed in separate experiments carried out over a period of approximately 3 years; one experiment was conducted with time point analyses (1.5 hours to 96 days) over a period of 3 months and in subsequent experiments samples were harvested on specific time points ranging from 10&#x02013;26 days. Although many differentially regulated proteins were detected as early as 1.5 hrs post infection and at several successive time points, most proteins in 1.5 to 4 hrs' gels were not quantifiable due to small quantities. For detailed analyses, we selected 33 gels from a large number of gels run on different IEF (pH 3&#x02013;10 &#x00026; 4&#x02013;7) and SDS -PAGE gradients. These included at different time points ranging from 1.5 hours to 96 days plus numerous samples from 10&#x02013;26 days as these samples yielded higher quantities and were detected in multiple gels. As indicated earlier, we also used chronically HIV-infected cells and control uninfected cells as standard references for all gels.</p><p>All proteins from HIV-infected cells were compared with those expressed in the uninfected counterpart cells at different time points. <italic>Only</italic> those proteins that were reproducibly detected in multiple gels were selected for bioinformatics and statistical analyses. To obtain a more accurate dataset for each of the upregulated or downregulated protein in HIV-infected cells we calculated standard deviations of the mean values from the range of <italic>normalized</italic> quantities expressed in both HIV-infected and uninfected samples tested. A plus and minus one standard deviation of the mean value is illustrated by a bar within the graph for each protein (<xref ref-type="fig" rid="pone-0003003-g002">Figures 2</xref> and <xref ref-type="fig" rid="pone-0003003-g003">3</xref>).</p></sec><sec id="s3c"><title>MALDI-TOF Mass Spectrometry (MS)</title><p>All differentially regulated spots (i.e. upregulated, downregulated or <italic>de novo</italic> synthesized proteins post-HIV infection) and some common spots present both in the infected and uninfected cells were selected for protein identification by MALDI-TOF MS. All spots were excised form gels and washed successively with water, ammonium bicarbonate (25 mM, 1&#x02236;1(v/v) acetylnitrite (ACN):25 mM ammonium bicarbomnate), and 100&#x00025; ACN. The gels were then vacuum-dried and stored in the refrigerator until MS was performed. Prior to MS the dried gels were reconstituted in 25 mM ammonium bicarbonate containing 0.1 mg ultra-pure, MS-grade trypsin (pH 7.8) (Promega) and incubated overnight to extract peptides. Peptide fingerprints of in-gel digests were analyzed by MALDI-TOF-MS according to the manufacturer's protocols (Applied Biosystems). All annotated spectra were analyzed using PS1 software (Applied Biosystems) and MASCOT (Matrix Science, London). Embedded in these programs are biostatistical and analytical systems to select differentially expressed peaks (MS signals). The search parameters included mammals and human. All spectra were linearly calibrated using a two-point calibration with internal standards corresponding to autoproteolytic tryptic peaks. To quantify the differences in calibration between the reference spots and experimental protein spots on the plate, we applied the derived &#x02018;topological map&#x02019; to afford the best calibration throughout the plate while using a single calibrant.</p></sec><sec id="s3d"><title>Validation of Protein Functionality by the use of an HIV-Inhibitor</title><p>To validate the functionality of both viral and cellular proteins expressed in HIV-infected cells, we tested the same H9 T- cells described above and infected these with the same X4 HIV strain that was used for all proteomics studies. Cells were divided into two aliquots; one was infected with HIV and the other was used as uninfected control. The virus in the supernatant was removed after 3 days and cells were placed in new flask after washing with PBS. Each set of cultures was then divided into 4 flasks each (i. e. 8 flasks); two each (i.e. duplicates) of the HIV-infected and uninfected (control) cultures were maintained as experimental controls and separate replicates of each were treated with10 ug/ml of Azidothymidine (AZT or Zidovudine) a reverse transcriptase inhibitor (gift from GlaxoSmithKline/Burroughs Wellcome). This drug has been shown to inhibit HIV replication <italic>in vitro</italic> and has been used to treat HIV infected individuals alone and in combination with other drugs <xref rid="pone.0003003-Wright1" ref-type="bibr">[137]</xref>, <xref rid="pone.0003003-Park3" ref-type="bibr">[138]</xref>. After 48 hrs, proteins were extracted from all cultures as described above and all samples from the treated, untreated, HIV- infected and uninfected counterpart cultures were tested by proteomics analyses as described above.</p><p>The ability of HIV to replicate or to be inhibited by AZT was tested by the presence or absence of p24 antigen in the supernatant and in the cellular protein fractions by proteomics technology (<xref ref-type="fig" rid="pone-0003003-g005">Figure 5</xref>). No HIV p24 was detected in HIV-infected cells treated with AZT whereas HIV-infected untreated cells produced significant quantities of this protein indicating that HIV replication was inhibited and the proteomics results are significant. Further, since the expression of APOB protein was not affected by the antiviral drug treatment it indicated that both low abundant p24 and high abundant proteins can be detected by our proteomics technology.</p></sec><sec id="s3e"><title>Statistical Analyses and Protein- Interaction pathways involved in Lipid Metabolism</title><p>The significance of proteins involved in lipid metabolism was possible only by analyzing massive amounts of data on HIV-modulated cellular proteomes overtime for a very long period. Several hundred differentially expressed proteins (upregulated or downregulated or <italic>de novo</italic> synthesized proteins post-HIV infection) were identified by proteomics analyses and each was categorized according to the known function/s in the global databases of human proteins (UniProt/SwissProt). Standard deviations of mean values were calculated for each protein quantity and are represented by bars within the graph (<xref ref-type="fig" rid="pone-0003003-g002">Figure 2</xref> &#x00026; <xref ref-type="fig" rid="pone-0003003-g003">3</xref>). By the use of bioinformatics and computational program &#x0201c;Functional Repository of Humans Genes and Proteins&#x0201d; (Ingenuity Systems Inc.), biological functions of each protein were validated in relation to the proteins involved in lipid synthesis, production, quantity, cleavage, transport, secretion, and/or lipid oxidation. These programs also calculated the likelihood of whether a particular function in &#x0201c;Global Functional Analysis and Global Canonical Pathways&#x0201d; was due to a random chance or a set of proteins identified experimentally could be statistically associated with specific biological processes involved in lipid metabolism.</p><p>Using 2&#x000d7;2 contingency tables, the p-values of all experimentally identified proteins were calculated by the Global Functional Analysis programs in relation to the total number of proteins that have been shown to be associated with human lipid metabolism. The p-values of proteins involved in the lipid metabolism were calculated by using the right-tailed Fisher Exact Test and Ingenuity Pathway Analysis Systems. These analyses identified a coordinated expression of 18 proteins with statistical significance (<italic>p</italic> values &#x0200a;=&#x0200a;&#x0003c;0.05 as indicators) in relation to global and local lipid metabolism-related functions<bold>.</bold> However, All proteins selected for this study had p-values &#x0003c;0.02.</p><p>For protein-interaction pathway analyses, we have used the Ingenuity Pathway Analysis (IPA) System and Strategene Pathway Architect (SPA) software. All 18 proteins involved in the lipid metabolism were used to construct the pathways according to manufacturer's instructions. One of the pathways made by the SPA is presented in <xref ref-type="fig" rid="pone-0003003-g004">Figures 4</xref>.</p></sec></sec></body><back><ack><p>We thank the Ingenuity System Inc and Ingenuity Pathway Analysis Systems for enabling us to use their extensive databases for analyzing the biological significance and confirming functional categories of each protein in relation to human lipid metabolism; the manufacturers of Strategene are also acknowledged for enabling us to use their Pathway Architect program; Zisu Mao and Jane M.C. Chan are recognized for technical assistance with two-dimensional gel electrophoresis and mass spectrometry respectively; the help of Adil Hussain and Karen Lau are acknowledged for construction of protein-interaction pathways involved in lipid metabolism; thanks to Prof. Linda Chan for confirming the calculated standard deviations; and the summer students Asad Arastu, Varun Devraj, Sarah Hussain Ashwan Mehra and Rahim Hashim for their help with figures and tables;</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>The Rasheed Research and Endowment Funds at the University of Southern California (USC) sponsored this research. The funders (USC) had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0003003-Carr1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carr</surname><given-names>A</given-names></name><name><surname>Workman</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>DE</given-names></name><name><surname>Hoy</surname><given-names>J</given-names></name><name><surname>Hudson</surname><given-names>J</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.</article-title>
<source>JAMA</source>
<volume>288</volume>
<fpage>207</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="pmid">12095385</pub-id></element-citation></ref><ref id="pone.0003003-Fisher1"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fisher</surname><given-names>SD</given-names></name><name><surname>Miller</surname><given-names>TL</given-names></name><name><surname>Lipshultz</surname><given-names>SE</given-names></name></person-group>
<year>2006</year>
<article-title>Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis.</article-title>
<source>Atherosclerosis</source>
<volume>185</volume>
<fpage>1</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="pmid">16297390</pub-id></element-citation></ref><ref id="pone.0003003-Lainka1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lainka</surname><given-names>E</given-names></name><name><surname>Oezbek</surname><given-names>S</given-names></name><name><surname>Falck</surname><given-names>M</given-names></name><name><surname>Ndagijimana</surname><given-names>J</given-names></name><name><surname>Niehues</surname><given-names>T</given-names></name></person-group>
<year>2002</year>
<article-title>Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.</article-title>
<source>Pediatrics</source>
<volume>110</volume>
<fpage>e56</fpage>
<pub-id pub-id-type="pmid">12415062</pub-id></element-citation></ref><ref id="pone.0003003-Carter1"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carter</surname><given-names>VM</given-names></name><name><surname>Hoy</surname><given-names>JF</given-names></name><name><surname>Bailey</surname><given-names>M</given-names></name><name><surname>Colman</surname><given-names>PG</given-names></name><name><surname>Nyulasi</surname><given-names>I</given-names></name><etal/></person-group>
<year>2001</year>
<article-title>The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV.</article-title>
<source>Med</source>
<volume>2</volume>
<fpage>174</fpage>
<lpage>180</lpage>
</element-citation></ref><ref id="pone.0003003-Constans1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Constans</surname><given-names>J</given-names></name><name><surname>Pellegrin</surname><given-names>JL</given-names></name><name><surname>Peuchant</surname><given-names>E</given-names></name><name><surname>Dumon</surname><given-names>MF</given-names></name><name><surname>Pellegrin</surname><given-names>I</given-names></name><etal/></person-group>
<year>1994</year>
<article-title>Plasma lipids in HIV-infected patients: a prospective study in 95 patients.</article-title>
<source>Eur. J. Clin. Invest</source>
<volume>24</volume>
<fpage>416</fpage>
<lpage>420</lpage>
<pub-id pub-id-type="pmid">7957495</pub-id></element-citation></ref><ref id="pone.0003003-Tanwani1"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tanwani</surname><given-names>LK</given-names></name><name><surname>Mokshagundam</surname><given-names>SL</given-names></name></person-group>
<year>2003</year>
<article-title>Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection.</article-title>
<source>South. Med. J</source>
<volume>96</volume>
<fpage>180</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="pmid">12630645</pub-id></element-citation></ref><ref id="pone.0003003-Leonard1"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leonard</surname><given-names>EG</given-names></name><name><surname>McComsey</surname><given-names>GA</given-names></name></person-group>
<year>2005</year>
<article-title>Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.</article-title>
<source>Infect. Dis. Clin. North Am</source>
<volume>19</volume>
<fpage>713</fpage>
<lpage>729</lpage>
<pub-id pub-id-type="pmid">16102657</pub-id></element-citation></ref><ref id="pone.0003003-Bukrinsky1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bukrinsky</surname><given-names>M</given-names></name><name><surname>Sviridov</surname><given-names>D</given-names></name></person-group>
<year>2006</year>
<article-title>Human immunodeficiency virus infection and macrophage cholesterol metabolism.</article-title>
<source>J Leukoc. Biol</source>
<volume>80</volume>
<fpage>1044</fpage>
<lpage>1051</lpage>
<pub-id pub-id-type="pmid">17056763</pub-id></element-citation></ref><ref id="pone.0003003-onsoVillaverde1"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>onso-Villaverde</surname><given-names>C</given-names></name><name><surname>Segues</surname><given-names>T</given-names></name><name><surname>Coll-Crespo</surname><given-names>B</given-names></name><name><surname>Perez-Bernalte</surname><given-names>R</given-names></name><name><surname>Rabassa</surname><given-names>A</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>High-density lipoprotein concentrations relate to the clinical course of HIV viral load in patients undergoing antiretroviral therapy.</article-title>
<source>AIDS</source>
<volume>17</volume>
<fpage>1173</fpage>
<lpage>1178</lpage>
<pub-id pub-id-type="pmid">12819519</pub-id></element-citation></ref><ref id="pone.0003003-Coll1"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Coll</surname><given-names>B</given-names></name><name><surname>Parra</surname><given-names>S</given-names></name><name><surname>onso-Villaverde</surname><given-names>C</given-names></name><name><surname>de</surname><given-names>GE</given-names></name><name><surname>Aragones</surname><given-names>G</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1.</article-title>
<source>Cytokine</source>
<volume>34</volume>
<fpage>51</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="pmid">16697654</pub-id></element-citation></ref><ref id="pone.0003003-Barbaro1"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barbaro</surname><given-names>G</given-names></name></person-group>
<year>2002</year>
<article-title>HIV infection, antiretroviral therapy and cardiovascular risk.</article-title>
<source>J. Cardiovasc. Risk</source>
<volume>9</volume>
<fpage>295</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="pmid">12394324</pub-id></element-citation></ref><ref id="pone.0003003-Krishnaswamy1"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krishnaswamy</surname><given-names>G</given-names></name><name><surname>Chi</surname><given-names>DS</given-names></name><name><surname>Kelley</surname><given-names>JL</given-names></name><name><surname>Sarubbi</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>JK</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>The cardiovascular and metabolic complications of HIV infection.</article-title>
<source>Cardiol. Rev</source>
<volume>8</volume>
<fpage>260</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="pmid">11174904</pub-id></element-citation></ref><ref id="pone.0003003-Maggi1"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maggi</surname><given-names>P</given-names></name><name><surname>Maserati</surname><given-names>R</given-names></name><name><surname>Antonelli</surname><given-names>G</given-names></name></person-group>
<year>2006</year>
<article-title>Atherosclerosis in HIV patients: a new face for an old disease?</article-title>
<source>AIDS Rev</source>
<volume>8</volume>
<fpage>204</fpage>
<lpage>209</lpage>
<pub-id pub-id-type="pmid">17219735</pub-id></element-citation></ref><ref id="pone.0003003-Raulin1"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raulin</surname><given-names>J</given-names></name></person-group>
<year>2002</year>
<article-title>Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy.</article-title>
<source>Prog. Lipid Res</source>
<volume>41</volume>
<fpage>27</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="pmid">11694268</pub-id></element-citation></ref><ref id="pone.0003003-Barbaro2"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barbaro</surname><given-names>G</given-names></name></person-group>
<year>2007</year>
<article-title>Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome.</article-title>
<source>Curr. Pharm. Des</source>
<volume>13</volume>
<fpage>2208</fpage>
<lpage>2213</lpage>
<pub-id pub-id-type="pmid">17627554</pub-id></element-citation></ref><ref id="pone.0003003-Umpleby1"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Umpleby</surname><given-names>AM</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Stolinski</surname><given-names>M</given-names></name><name><surname>Shojaee-Moradie</surname><given-names>F</given-names></name><name><surname>Jackson</surname><given-names>NC</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Low density lipoprotein apolipoprotein B metabolism in treatment-naive HIV patients and patients on antiretroviral therapy. Antivir.</article-title>
<source>Ther</source>
<volume>10</volume>
<fpage>663</fpage>
<lpage>670</lpage>
</element-citation></ref><ref id="pone.0003003-BenRomano1"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ben-Romano</surname><given-names>R</given-names></name><name><surname>Rudich</surname><given-names>A</given-names></name><name><surname>Tirosh</surname><given-names>A</given-names></name><name><surname>Potashnik</surname><given-names>R</given-names></name><name><surname>Sasaoka</surname><given-names>T</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta.</article-title>
<source>Diabetologia</source>
<volume>47</volume>
<fpage>1107</fpage>
<lpage>1117</lpage>
<pub-id pub-id-type="pmid">15168016</pub-id></element-citation></ref><ref id="pone.0003003-Carr2"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carr</surname><given-names>A</given-names></name><name><surname>Samaras</surname><given-names>K</given-names></name><name><surname>Chisholm</surname><given-names>DJ</given-names></name><name><surname>Cooper</surname><given-names>DA</given-names></name></person-group>
<year>1998</year>
<article-title>Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.</article-title>
<source>Lancet</source>
<volume>&#x00025;20;351</volume>
<fpage>1881</fpage>
<lpage>1883</lpage>
</element-citation></ref><ref id="pone.0003003-Hurlimann1"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hurlimann</surname><given-names>D</given-names></name><name><surname>Weber</surname><given-names>R</given-names></name><name><surname>Enseleit</surname><given-names>F</given-names></name><name><surname>Luscher</surname><given-names>TF</given-names></name></person-group>
<year>2005</year>
<article-title>[HIV infection, antiretroviral therapy, and endothelium].</article-title>
<source>Herz</source>
<volume>30</volume>
<fpage>472</fpage>
<lpage>480</lpage>
<pub-id pub-id-type="pmid">16170677</pub-id></element-citation></ref><ref id="pone.0003003-Currier1"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Currier</surname><given-names>J</given-names></name><name><surname>Scherzer</surname><given-names>R</given-names></name><name><surname>Bacchetti</surname><given-names>P</given-names></name><name><surname>Heymsfield</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Regional Adipose Tissue and Lipid and Lipoprotein Levels in HIV-Infected Women.</article-title>
<source>J. Acquir. Immune. Defic. Syndr</source>
</element-citation></ref><ref id="pone.0003003-Lorenz1"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lorenz</surname><given-names>MW</given-names></name><name><surname>Stephan</surname><given-names>C</given-names></name><name><surname>Harmjanz</surname><given-names>A</given-names></name><name><surname>Staszewski</surname><given-names>S</given-names></name><name><surname>Buehler</surname><given-names>A</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis.</article-title>
<source>Atherosclerosis</source>
</element-citation></ref><ref id="pone.0003003-Gomez1"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gomez</surname><given-names>E</given-names></name></person-group>
<year>1998</year>
<article-title>Wasting and body changes: what do we know so far?</article-title>
<source>Newsline. People. AIDS Coalit. N. Y. :</source>
<volume>34-6.</volume>
<fpage>34</fpage>
<lpage>36</lpage>
</element-citation></ref><ref id="pone.0003003-Carr3"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carr</surname><given-names>A</given-names></name></person-group>
<year>2000</year>
<article-title>HIV protease inhibitor-related lipodystrophy syndrome.</article-title>
<source>Clin. Infect. Dis</source>
<volume>30</volume>
<issue>Suppl 2:S135-42.</issue>
<fpage>S135</fpage>
<lpage>S142</lpage>
<pub-id pub-id-type="pmid">10860898</pub-id></element-citation></ref><ref id="pone.0003003-Grinspoon1"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grinspoon</surname><given-names>SK</given-names></name></person-group>
<year>2005</year>
<article-title>Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.</article-title>
<source>Am. J Med</source>
<volume>118</volume>
<issue>Suppl 2</issue>
<fpage>23S</fpage>
<lpage>28S</lpage>
<pub-id pub-id-type="pmid">15903292</pub-id></element-citation></ref><ref id="pone.0003003-Behrens1"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Behrens</surname><given-names>GM</given-names></name><name><surname>Stoll</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>RE</given-names></name></person-group>
<year>2000</year>
<article-title>Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?</article-title>
<source>Drug Saf</source>
<volume>23</volume>
<fpage>57</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="pmid">10915032</pub-id></element-citation></ref><ref id="pone.0003003-Vigouroux1"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vigouroux</surname><given-names>C</given-names></name><name><surname>Gharakhanian</surname><given-names>S</given-names></name><name><surname>Salhi</surname><given-names>Y</given-names></name><name><surname>Nguyen</surname><given-names>TH</given-names></name><name><surname>Chevenne</surname><given-names>D</given-names></name><etal/></person-group>
<year>1999</year>
<article-title>Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).</article-title>
<source>Diabetes Metab</source>
<volume>25</volume>
<fpage>225</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="pmid">10499191</pub-id></element-citation></ref><ref id="pone.0003003-Mallon1"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mallon</surname><given-names>PW</given-names></name></person-group>
<year>2007</year>
<article-title>Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy.</article-title>
<source>AIDS Rev</source>
<volume>9</volume>
<fpage>3</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="pmid">17474309</pub-id></element-citation></ref><ref id="pone.0003003-Behrens2"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Behrens</surname><given-names>G</given-names></name><name><surname>Dejam</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Balks</surname><given-names>HJ</given-names></name><name><surname>Brabant</surname><given-names>G</given-names></name><etal/></person-group>
<year>1999</year>
<article-title>Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.</article-title>
<source>AIDS</source>
<volume>13</volume>
<fpage>F63</fpage>
<lpage>F70</lpage>
<pub-id pub-id-type="pmid">10416516</pub-id></element-citation></ref><ref id="pone.0003003-Hazan1"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hazan</surname><given-names>U</given-names></name><name><surname>Romero</surname><given-names>IA</given-names></name><name><surname>Cancello</surname><given-names>R</given-names></name><name><surname>Valente</surname><given-names>S</given-names></name><name><surname>Perrin</surname><given-names>V</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Human adipose cells express CD4, CXCR4, and CCR5 [corrected] receptors: a new target cell type for the immunodeficiency virus-1?</article-title>
<source>FASEB J</source>
<volume>16</volume>
<fpage>1254</fpage>
<lpage>1256</lpage>
<pub-id pub-id-type="pmid">12153994</pub-id></element-citation></ref><ref id="pone.0003003-Desruisseaux1"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Desruisseaux</surname><given-names>MS</given-names></name><name><surname>Nagajyothi</surname></name><name><surname>Trujillo</surname><given-names>ME</given-names></name><name><surname>Tanowitz</surname><given-names>HB</given-names></name><name><surname>Scherer</surname><given-names>PE</given-names></name></person-group>
<year>2007</year>
<article-title>Adipocyte, adipose tissue, and infectious disease.</article-title>
<source>Infect. Immun</source>
<volume>75</volume>
<fpage>1066</fpage>
<lpage>1078</lpage>
<pub-id pub-id-type="pmid">17118983</pub-id></element-citation></ref><ref id="pone.0003003-Maurin1"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maurin</surname><given-names>T</given-names></name><name><surname>Saillan-Barreau</surname><given-names>C</given-names></name><name><surname>Cousin</surname><given-names>B</given-names></name><name><surname>Casteilla</surname><given-names>L</given-names></name><name><surname>Doglio</surname><given-names>A</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Tumor necrosis factor-alpha stimulates HIV-1 production in primary culture of human adipocytes.</article-title>
<source>Exp. Cell Res</source>
<volume>304</volume>
<fpage>544</fpage>
<lpage>551</lpage>
<pub-id pub-id-type="pmid">15748898</pub-id></element-citation></ref><ref id="pone.0003003-de1"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de</surname><given-names>FS</given-names></name><name><surname>Mozaffarian</surname><given-names>D</given-names></name></person-group>
<year>2008</year>
<article-title>The Perfect Storm: Obesity, Adipocyte Dysfunction, and Metabolic Consequences.</article-title>
<source>Clin. Chem</source>
</element-citation></ref><ref id="pone.0003003-Xu1"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Barnes</surname><given-names>GT</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Tan</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.</article-title>
<source>J. Clin. Invest</source>
<volume>112</volume>
<fpage>1821</fpage>
<lpage>1830</lpage>
<pub-id pub-id-type="pmid">14679177</pub-id></element-citation></ref><ref id="pone.0003003-Bonnet1"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bonnet</surname><given-names>E</given-names></name><name><surname>Genoux</surname><given-names>A</given-names></name><name><surname>Bernard</surname><given-names>J</given-names></name><name><surname>Fauvel</surname><given-names>J</given-names></name><name><surname>Massip</surname><given-names>P</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy.</article-title>
<source>Clin. Chem. Lab Med</source>
<volume>45</volume>
<fpage>815</fpage>
<lpage>821</lpage>
<pub-id pub-id-type="pmid">17617020</pub-id></element-citation></ref><ref id="pone.0003003-Rajala1"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rajala</surname><given-names>MW</given-names></name><name><surname>Scherer</surname><given-names>PE</given-names></name></person-group>
<year>2003</year>
<article-title>Minireview: The adipocyte&#x02013;at the crossroads of energy homeostasis, inflammation, and atherosclerosis.</article-title>
<source>Endocrinology</source>
<volume>144</volume>
<fpage>3765</fpage>
<lpage>3773</lpage>
<pub-id pub-id-type="pmid">12933646</pub-id></element-citation></ref><ref id="pone.0003003-Murray1"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murray</surname><given-names>I</given-names></name><name><surname>Havel</surname><given-names>PJ</given-names></name><name><surname>Sniderman</surname><given-names>AD</given-names></name><name><surname>Cianflone</surname><given-names>K</given-names></name></person-group>
<year>2000</year>
<article-title>Reduced body weight, adipose tissue, and leptin levels despite increased energy intake in female mice lacking acylation-stimulating protein.</article-title>
<source>Endocrinology</source>
<volume>141</volume>
<fpage>1041</fpage>
<lpage>1049</lpage>
<pub-id pub-id-type="pmid">10698180</pub-id></element-citation></ref><ref id="pone.0003003-Ng1"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ng</surname><given-names>TW</given-names></name><name><surname>Watts</surname><given-names>GF</given-names></name><name><surname>Farvid</surname><given-names>MS</given-names></name><name><surname>Chan</surname><given-names>DC</given-names></name><name><surname>Barrett</surname><given-names>PH</given-names></name></person-group>
<year>2005</year>
<article-title>Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics?</article-title>
<source>Diabetes</source>
<volume>54</volume>
<fpage>795</fpage>
<lpage>802</lpage>
<pub-id pub-id-type="pmid">15734858</pub-id></element-citation></ref><ref id="pone.0003003-Ono1"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ono</surname><given-names>A</given-names></name><name><surname>Freed</surname><given-names>EO</given-names></name></person-group>
<year>2001</year>
<article-title>Plasma membrane rafts play a critical role in HIV-1 assembly and release.</article-title>
<source>Proc. Natl. Acad. Sci. U. S. A</source>
<volume>98</volume>
<fpage>13925</fpage>
<lpage>13930</lpage>
<pub-id pub-id-type="pmid">11717449</pub-id></element-citation></ref><ref id="pone.0003003-Liao1"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Cimakasky</surname><given-names>LM</given-names></name><name><surname>Hampton</surname><given-names>R</given-names></name><name><surname>Nguyen</surname><given-names>DH</given-names></name><name><surname>Hildreth</surname><given-names>JE</given-names></name></person-group>
<year>2001</year>
<article-title>Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1.</article-title>
<source>AIDS Res Hum. Retroviruses</source>
<volume>17</volume>
<fpage>1009</fpage>
<lpage>1019</lpage>
<pub-id pub-id-type="pmid">11485618</pub-id></element-citation></ref><ref id="pone.0003003-Vidalain1"><label>40</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vidalain</surname><given-names>PO</given-names></name><name><surname>Azocar</surname><given-names>O</given-names></name><name><surname>Servet-Delprat</surname><given-names>C</given-names></name><name><surname>Rabourdin-Combe</surname><given-names>C</given-names></name><name><surname>Gerlier</surname><given-names>D</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>CD40 signaling in human dendritic cells is initiated within membrane rafts.</article-title>
<source>EMBO J</source>
<volume>19</volume>
<fpage>3304</fpage>
<lpage>3313</lpage>
<pub-id pub-id-type="pmid">10880443</pub-id></element-citation></ref><ref id="pone.0003003-Park1"><label>41</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>TS</given-names></name><name><surname>Yamashita</surname><given-names>H</given-names></name><name><surname>Blaner</surname><given-names>WS</given-names></name><name><surname>Goldberg</surname><given-names>IJ</given-names></name></person-group>
<year>2007</year>
<article-title>Lipids in the heart: a source of fuel and a source of toxins.</article-title>
<source>Curr. Opin. Lipidol</source>
<volume>18</volume>
<fpage>277</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="pmid">17495601</pub-id></element-citation></ref><ref id="pone.0003003-Park2"><label>42</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>JJ</given-names></name><name><surname>Kang</surname><given-names>SJ</given-names></name><name><surname>De Silva</surname><given-names>AD</given-names></name><name><surname>Stanic</surname><given-names>AK</given-names></name><name><surname>Casorati</surname><given-names>G</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Lipid-protein interactions: Biosynthetic assembly of CD1 with lipids in the endoplasmic reticulum is evolutionarily conserved.</article-title>
<source>PNAS</source>
<volume>101</volume>
<fpage>1022</fpage>
<lpage>1026</lpage>
<pub-id pub-id-type="pmid">14722359</pub-id></element-citation></ref><ref id="pone.0003003-Miyanari1"><label>43</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miyanari</surname><given-names>Y</given-names></name><name><surname>Atsuzawa</surname><given-names>K</given-names></name><name><surname>Usuda</surname><given-names>N</given-names></name><name><surname>Watashi</surname><given-names>K</given-names></name><name><surname>Hishiki</surname><given-names>T</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>The lipid droplet is an important organelle for hepatitis C virus production.</article-title>
<source>Nat. Cell Biol</source>
<volume>9</volume>
<fpage>1089</fpage>
<lpage>1097</lpage>
<pub-id pub-id-type="pmid">17721513</pub-id></element-citation></ref><ref id="pone.0003003-Brugger1"><label>44</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brugger</surname><given-names>B</given-names></name><name><surname>Glass</surname><given-names>B</given-names></name><name><surname>Haberkant</surname><given-names>P</given-names></name><name><surname>Leibrecht</surname><given-names>I</given-names></name><name><surname>Wieland</surname><given-names>FT</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>The HIV lipidome: a raft with an unusual composition.</article-title>
<source>Proc. Natl. Acad. Sci. U. S. A</source>
<volume>103</volume>
<fpage>2641</fpage>
<lpage>2646</lpage>
<pub-id pub-id-type="pmid">16481622</pub-id></element-citation></ref><ref id="pone.0003003-Wang1"><label>45</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name></person-group>
<year>2007</year>
<article-title>Molecular regulation of macrophage reverse cholesterol transport.</article-title>
<source>Curr. Opin. Cardiol</source>
<volume>22</volume>
<fpage>368</fpage>
<lpage>372</lpage>
<pub-id pub-id-type="pmid">17556891</pub-id></element-citation></ref><ref id="pone.0003003-Rothblat1"><label>46</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rothblat</surname><given-names>GH</given-names></name><name><surname>Mahlberg</surname><given-names>FH</given-names></name><name><surname>Johnson</surname><given-names>WJ</given-names></name><name><surname>Phillips</surname><given-names>MC</given-names></name></person-group>
<year>1992</year>
<article-title>Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux.</article-title>
<source>J. Lipid Res</source>
<volume>33</volume>
<fpage>1091</fpage>
<lpage>1097</lpage>
<pub-id pub-id-type="pmid">1431592</pub-id></element-citation></ref><ref id="pone.0003003-Mujawar1"><label>47</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mujawar</surname><given-names>Z</given-names></name><name><surname>Rose</surname><given-names>H</given-names></name><name><surname>Morrow</surname><given-names>MP</given-names></name><name><surname>Pushkarsky</surname><given-names>T</given-names></name><name><surname>Dubrovsky</surname><given-names>L</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Human immunodeficiency virus impairs reverse cholesterol transport from macrophages.</article-title>
<source>PLoS. Biol</source>
<volume>4</volume>
<fpage>e365</fpage>
<pub-id pub-id-type="pmid">17076584</pub-id></element-citation></ref><ref id="pone.0003003-Grunfeld1"><label>48</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grunfeld</surname><given-names>C</given-names></name><name><surname>Pang</surname><given-names>M</given-names></name><name><surname>Doerrler</surname><given-names>W</given-names></name><name><surname>Shigenaga</surname><given-names>JK</given-names></name><name><surname>Jensen</surname><given-names>P</given-names></name><etal/></person-group>
<year>1992</year>
<article-title>Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.</article-title>
<source>J. Clin. Endocrinol. Metab</source>
<volume>74</volume>
<fpage>1045</fpage>
<lpage>1052</lpage>
<pub-id pub-id-type="pmid">1373735</pub-id></element-citation></ref><ref id="pone.0003003-Arnedo1"><label>49</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arnedo</surname><given-names>M</given-names></name><name><surname>Taffe</surname><given-names>P</given-names></name><name><surname>Sahli</surname><given-names>R</given-names></name><name><surname>Furrer</surname><given-names>H</given-names></name><name><surname>Hirschel</surname><given-names>B</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.</article-title>
<source>Pharmacogenet. Genomics</source>
<volume>17</volume>
<fpage>755</fpage>
<lpage>764</lpage>
<pub-id pub-id-type="pmid">17700364</pub-id></element-citation></ref><ref id="pone.0003003-Giralt1"><label>50</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giralt</surname><given-names>M</given-names></name><name><surname>Domingo</surname><given-names>P</given-names></name><name><surname>Guallar</surname><given-names>JP</given-names></name><name><surname>de la Concepcion</surname><given-names>ML</given-names></name><name><surname>Alegre</surname><given-names>M</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy.</article-title>
<source>Antivir. Ther</source>
<volume>11</volume>
<fpage>729</fpage>
<lpage>740</lpage>
<pub-id pub-id-type="pmid">17310817</pub-id></element-citation></ref><ref id="pone.0003003-Mallon2"><label>51</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mallon</surname><given-names>PW</given-names></name></person-group>
<year>2006</year>
<article-title>Antiretroviral therapy and dyslipidaemia: unlocking the code.</article-title>
<source>PLoS. Med</source>
<volume>3</volume>
<fpage>e85</fpage>
<pub-id pub-id-type="pmid">16420104</pub-id></element-citation></ref><ref id="pone.0003003-Kadiu1"><label>52</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kadiu</surname><given-names>I</given-names></name><name><surname>Ricardo-Dukelow</surname><given-names>M</given-names></name><name><surname>Ciborowski</surname><given-names>P</given-names></name><name><surname>Gendelman</surname><given-names>HE</given-names></name></person-group>
<year>2007</year>
<article-title>Cytoskeletal protein transformation in HIV-1-infected macrophage giant cells.</article-title>
<source>J. Immunol</source>
<volume>178</volume>
<fpage>6404</fpage>
<lpage>6415</lpage>
<pub-id pub-id-type="pmid">17475870</pub-id></element-citation></ref><ref id="pone.0003003-Hodgetts1"><label>53</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hodgetts</surname><given-names>A</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name><name><surname>Kroll</surname><given-names>JS</given-names></name><name><surname>Langford</surname><given-names>PR</given-names></name></person-group>
<year>2007</year>
<article-title>Biomarker discovery in infectious diseases using SELDI.</article-title>
<source>Future. Microbiol</source>
<volume>2</volume>
<fpage>35</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="pmid">17661674</pub-id></element-citation></ref><ref id="pone.0003003-Molina1"><label>54</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Molina</surname><given-names>L</given-names></name><name><surname>Grimaldi</surname><given-names>M</given-names></name><name><surname>Robert-Hebmann</surname><given-names>V</given-names></name><name><surname>Espert</surname><given-names>L</given-names></name><name><surname>Varbanov</surname><given-names>M</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Proteomic analysis of the cellular responses induced in uninfected immune cells by cell-expressed X4 HIV-1 envelope.</article-title>
<source>Proteomics</source>
<volume>7</volume>
<fpage>3116</fpage>
<lpage>3130</lpage>
<pub-id pub-id-type="pmid">17676665</pub-id></element-citation></ref><ref id="pone.0003003-Laspiur1"><label>55</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Laspiur</surname><given-names>JP</given-names></name><name><surname>Anderson</surname><given-names>ER</given-names></name><name><surname>Ciborowski</surname><given-names>P</given-names></name><name><surname>Wojna</surname><given-names>V</given-names></name><name><surname>Rozek</surname><given-names>W</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>CSF proteomic fingerprints for HIV-associated cognitive impairment.</article-title>
<source>J. Neuroimmunol</source>
<volume>192</volume>
<fpage>157</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="pmid">17950469</pub-id></element-citation></ref><ref id="pone.0003003-Chan1"><label>56</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chan</surname><given-names>EY</given-names></name><name><surname>Qian</surname><given-names>WJ</given-names></name><name><surname>Diamond</surname><given-names>DL</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Gritsenko</surname><given-names>MA</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Quantitative analysis of human immunodeficiency virus type 1-infected CD4&#x0002b; cell proteome: dysregulated cell cycle progression and nuclear transport coincide with robust virus production.</article-title>
<source>J. Virol</source>
<volume>81</volume>
<fpage>7571</fpage>
<lpage>7583</lpage>
<pub-id pub-id-type="pmid">17494070</pub-id></element-citation></ref><ref id="pone.0003003-Ringrose1"><label>57</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ringrose</surname><given-names>JH</given-names></name><name><surname>Jeeninga</surname><given-names>RE</given-names></name><name><surname>Berkhout</surname><given-names>B</given-names></name><name><surname>Speijer</surname><given-names>D</given-names></name></person-group>
<year>2008</year>
<article-title>Proteomic studies reveal coordinated changes in T-cell expression patterns upon infection with human immunodeficiency virus type 1.</article-title>
<source>J. Virol</source>
<volume>82</volume>
<fpage>4320</fpage>
<lpage>4330</lpage>
<pub-id pub-id-type="pmid">18287243</pub-id></element-citation></ref><ref id="pone.0003003-Rasheed1"><label>58</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rasheed</surname><given-names>S</given-names></name><name><surname>Gottlieb</surname><given-names>AA</given-names></name><name><surname>Garry</surname><given-names>RF</given-names></name></person-group>
<year>1986</year>
<article-title>Cell killing by ultraviolet-inactivated human immunodeficiency virus.</article-title>
<source>Virology</source>
<volume>154</volume>
<fpage>395</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="pmid">3490050</pub-id></element-citation></ref><ref id="pone.0003003-Jensen1"><label>59</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jensen</surname><given-names>MA</given-names></name><name><surname>Li</surname><given-names>FS</given-names></name><name><surname>van 't Wout</surname><given-names>AB</given-names></name><name><surname>Nickle</surname><given-names>DC</given-names></name><name><surname>Shriner</surname><given-names>D</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.</article-title>
<source>J. Virol</source>
<volume>77</volume>
<fpage>13376</fpage>
<lpage>13388</lpage>
<pub-id pub-id-type="pmid">14645592</pub-id></element-citation></ref><ref id="pone.0003003-Stoiber1"><label>60</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stoiber</surname><given-names>H</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Janatova</surname><given-names>J</given-names></name><name><surname>Dierich</surname><given-names>MP</given-names></name></person-group>
<year>1995</year>
<article-title>Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1.</article-title>
<source>Immunobiology</source>
<volume>193</volume>
<fpage>98</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="pmid">7590866</pub-id></element-citation></ref><ref id="pone.0003003-Stoiber2"><label>61</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stoiber</surname><given-names>H</given-names></name><name><surname>Kacani</surname><given-names>L</given-names></name><name><surname>Speth</surname><given-names>C</given-names></name><name><surname>Wurzner</surname><given-names>R</given-names></name><name><surname>Dierich</surname><given-names>MP</given-names></name></person-group>
<year>2001</year>
<article-title>The supportive role of complement in HIV pathogenesis.</article-title>
<source>Immunol. Rev</source>
<volume>180:168-76.</volume>
<fpage>168</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="pmid">11414359</pub-id></element-citation></ref><ref id="pone.0003003-Susal1"><label>62</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Susal</surname><given-names>C</given-names></name><name><surname>Kirschfink</surname><given-names>M</given-names></name><name><surname>Kropelin</surname><given-names>M</given-names></name><name><surname>Daniel</surname><given-names>V</given-names></name><name><surname>Opelz</surname><given-names>G</given-names></name></person-group>
<year>1996</year>
<article-title>Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120.</article-title>
<source>Blood</source>
<volume>87</volume>
<fpage>2329</fpage>
<lpage>2336</lpage>
<pub-id pub-id-type="pmid">8630395</pub-id></element-citation></ref><ref id="pone.0003003-Wetsel1"><label>63</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wetsel</surname><given-names>RA</given-names></name><name><surname>Kildsgaard</surname><given-names>J</given-names></name><name><surname>Zsigmond</surname><given-names>E</given-names></name><name><surname>Liao</surname><given-names>W</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name></person-group>
<year>1999</year>
<article-title>Genetic deficiency of acylation stimulating protein (ASP(C3ades-Arg)) does not cause hyperapobetalipoproteinemia in mice.</article-title>
<source>J. Biol Chem</source>
<volume>274</volume>
<fpage>19429</fpage>
<lpage>19433</lpage>
<pub-id pub-id-type="pmid">10383458</pub-id></element-citation></ref><ref id="pone.0003003-Ducharme1"><label>64</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ducharme</surname><given-names>NA</given-names></name><name><surname>Bickel</surname><given-names>PE</given-names></name></person-group>
<year>2008</year>
<article-title>Lipid Droplets in Lipogenesis and Lipolysis.</article-title>
<source>Endocrinology</source>
</element-citation></ref><ref id="pone.0003003-Beach1"><label>65</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beach</surname><given-names>DC</given-names></name><name><surname>Flick</surname><given-names>PK</given-names></name></person-group>
<year>1982</year>
<article-title>Early effect of myo-inositol deficiency on fatty acid synthetic enzymes of rat liver.</article-title>
<source>Biochim. Biophys. Acta</source>
<volume>711</volume>
<fpage>452</fpage>
<lpage>459</lpage>
<pub-id pub-id-type="pmid">6125217</pub-id></element-citation></ref><ref id="pone.0003003-Moon1"><label>66</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moon</surname><given-names>YS</given-names></name><name><surname>Latasa</surname><given-names>MJ</given-names></name><name><surname>Griffin</surname><given-names>MJ</given-names></name><name><surname>Sul</surname><given-names>HS</given-names></name></person-group>
<year>2002</year>
<article-title>Suppression of fatty acid synthase promoter by polyunsaturated fatty acids.</article-title>
<source>J. Lipid Res</source>
<volume>43</volume>
<fpage>691</fpage>
<lpage>698</lpage>
<pub-id pub-id-type="pmid">11971939</pub-id></element-citation></ref><ref id="pone.0003003-Engstrom1"><label>67</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Engstrom</surname><given-names>G</given-names></name><name><surname>Hedblad</surname><given-names>B</given-names></name><name><surname>Janzon</surname><given-names>L</given-names></name><name><surname>Lindgarde</surname><given-names>F</given-names></name></person-group>
<year>2007</year>
<article-title>Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur. J. Cardiovasc.</article-title>
<source>Prev. Rehabil</source>
<volume>14</volume>
<fpage>392</fpage>
<lpage>397</lpage>
</element-citation></ref><ref id="pone.0003003-Ajjan1"><label>68</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ajjan</surname><given-names>R</given-names></name><name><surname>Grant</surname><given-names>PJ</given-names></name><name><surname>Futers</surname><given-names>TS</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Cymbalista</surname><given-names>CM</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Complement C3 and C-reactive protein levels in patients with stable coronary artery disease.</article-title>
<source>Thromb. Haemost</source>
<volume>94</volume>
<fpage>1048</fpage>
<lpage>1053</lpage>
<pub-id pub-id-type="pmid">16363249</pub-id></element-citation></ref><ref id="pone.0003003-Pendaries1"><label>69</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pendaries</surname><given-names>C</given-names></name><name><surname>Tronchere</surname><given-names>H</given-names></name><name><surname>Racaud-Sultan</surname><given-names>C</given-names></name><name><surname>Gaits-Iacovoni</surname><given-names>F</given-names></name><name><surname>Coronas</surname><given-names>S</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Emerging roles of phosphatidylinositol monophosphates in cellular signaling and trafficking.</article-title>
<source>Adv. Enzyme Regul</source>
<volume>45:201-14. Epub@2005 Jul 15.</volume>
<fpage>201</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="pmid">16023705</pub-id></element-citation></ref><ref id="pone.0003003-Anderson1"><label>70</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anderson</surname><given-names>RA</given-names></name><name><surname>Boronenkov</surname><given-names>IV</given-names></name><name><surname>Doughman</surname><given-names>SD</given-names></name><name><surname>Kunz</surname><given-names>J</given-names></name><name><surname>Loijens</surname><given-names>JC</given-names></name></person-group>
<year>1999</year>
<article-title>Phosphatidylinositol Phosphate Kinases, a Multifaceted Family of Signaling Enzymes.</article-title>
<source>J. Biol. Chem</source>
<volume>274</volume>
<fpage>9907</fpage>
<lpage>9910</lpage>
<pub-id pub-id-type="pmid">10187762</pub-id></element-citation></ref><ref id="pone.0003003-Yu1"><label>71</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Cassara</surname><given-names>J</given-names></name><name><surname>Weller</surname><given-names>PF</given-names></name></person-group>
<year>2000</year>
<article-title>Phosphatidylinositide 3-kinase localizes to cytoplasmic lipid bodies in human polymorphonuclear leukocytes and other myeloid-derived cells.</article-title>
<source>Blood</source>
<volume>95</volume>
<fpage>1078</fpage>
<lpage>1085</lpage>
<pub-id pub-id-type="pmid">10648425</pub-id></element-citation></ref><ref id="pone.0003003-Lamia1"><label>72</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lamia</surname><given-names>KA</given-names></name><name><surname>Peroni</surname><given-names>OD</given-names></name><name><surname>Kim</surname><given-names>YB</given-names></name><name><surname>Rameh</surname><given-names>LE</given-names></name><name><surname>Kahn</surname><given-names>BB</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Increased Insulin Sensitivity and Reduced Adiposity in Phosphatidylinositol 5-Phosphate 4-Kinase {beta}-/- Mice.</article-title>
<source>Mol. Cell. Biol</source>
<volume>24</volume>
<fpage>5080</fpage>
<lpage>5087</lpage>
<pub-id pub-id-type="pmid">15143198</pub-id></element-citation></ref><ref id="pone.0003003-Cheng1"><label>73</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>WH</given-names></name><name><surname>Ho</surname><given-names>YS</given-names></name><name><surname>Valentine</surname><given-names>BA</given-names></name><name><surname>Deborah</surname><given-names>A</given-names></name><name><surname>Combs</surname><given-names>J</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>Cellular Glutathione Peroxidase Is the Mediator of Body Selenium To Protect against Paraquat Lethality in Transgenic Mice.</article-title>
<source>J. Nutr</source>
<volume>128</volume>
<fpage>1070</fpage>
<lpage>1076</lpage>
<pub-id pub-id-type="pmid">9649587</pub-id></element-citation></ref><ref id="pone.0003003-Stephensen1"><label>74</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stephensen</surname><given-names>CB</given-names></name><name><surname>Marquis</surname><given-names>GS</given-names></name><name><surname>Douglas</surname><given-names>SD</given-names></name><name><surname>Kruzich</surname><given-names>LA</given-names></name><name><surname>Wilson</surname><given-names>CM</given-names></name></person-group>
<year>2007</year>
<article-title>Glutathione, glutathione peroxidase, and selenium status in HIV-positive and HIV-negative adolescents and young adults.</article-title>
<source>Am. J. Clin. Nutr</source>
<volume>85</volume>
<fpage>173</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="pmid">17209194</pub-id></element-citation></ref><ref id="pone.0003003-Zhao1"><label>75</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Olubajo</surname><given-names>B</given-names></name><name><surname>Taylor</surname><given-names>EW</given-names></name></person-group>
<year>2006</year>
<article-title>Functional studies of an HIV-1 encoded glutathione peroxidase.</article-title>
<source>Biofactors</source>
<volume>27</volume>
<fpage>93</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="pmid">17012767</pub-id></element-citation></ref><ref id="pone.0003003-Lewis1"><label>76</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>P</given-names></name><name><surname>Stefanovic</surname><given-names>N</given-names></name><name><surname>Pete</surname><given-names>J</given-names></name><name><surname>Calkin</surname><given-names>AC</given-names></name><name><surname>Giunti</surname><given-names>S</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice.</article-title>
<source>Circulation</source>
<volume>115</volume>
<fpage>2178</fpage>
<lpage>2187</lpage>
<pub-id pub-id-type="pmid">17420349</pub-id></element-citation></ref><ref id="pone.0003003-Feng1"><label>77</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Marnett</surname><given-names>LJ</given-names></name><name><surname>Tang</surname><given-names>MS</given-names></name></person-group>
<year>2006</year>
<article-title>Malondialdehyde, a major endogenous lipid peroxidation product, sensitizes human cells to UV- and BPDE-induced killing and mutagenesis through inhibition of nucleotide excision repair.</article-title>
<source>Mutat. Res</source>
<volume>601</volume>
<fpage>125</fpage>
<lpage>136</lpage>
<pub-id pub-id-type="pmid">16872641</pub-id></element-citation></ref><ref id="pone.0003003-McClung1"><label>78</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McClung</surname><given-names>JP</given-names></name><name><surname>Roneker</surname><given-names>CA</given-names></name><name><surname>Mu</surname><given-names>W</given-names></name><name><surname>Lisk</surname><given-names>DJ</given-names></name><name><surname>Langlais</surname><given-names>P</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase.</article-title>
<source>PNAS</source>
<volume>101</volume>
<fpage>8852</fpage>
<lpage>8857</lpage>
<pub-id pub-id-type="pmid">15184668</pub-id></element-citation></ref><ref id="pone.0003003-Shih1"><label>79</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shih</surname><given-names>SC</given-names></name><name><surname>Mullen</surname><given-names>A</given-names></name><name><surname>Abrams</surname><given-names>K</given-names></name><name><surname>Mukhopadhyay</surname><given-names>D</given-names></name><name><surname>Claffey</surname><given-names>KP</given-names></name></person-group>
<year>1999</year>
<article-title>Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells.</article-title>
<source>J. Biol. Chem</source>
<volume>274</volume>
<fpage>15407</fpage>
<lpage>15414</lpage>
<pub-id pub-id-type="pmid">10336429</pub-id></element-citation></ref><ref id="pone.0003003-Wakasaki1"><label>80</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wakasaki</surname><given-names>H</given-names></name><name><surname>Koya</surname><given-names>D</given-names></name><name><surname>Schoen</surname><given-names>FJ</given-names></name><name><surname>Jirousek</surname><given-names>MR</given-names></name><name><surname>Ways</surname><given-names>DK</given-names></name><etal/></person-group>
<year>1997</year>
<article-title>Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy.</article-title>
<source>Proc. Natl. Acad. Sci. U. S. A</source>
<volume>94</volume>
<fpage>9320</fpage>
<lpage>9325</lpage>
<pub-id pub-id-type="pmid">9256480</pub-id></element-citation></ref><ref id="pone.0003003-Rohlfs1"><label>81</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rohlfs</surname><given-names>EM</given-names></name><name><surname>Louie</surname><given-names>DS</given-names></name><name><surname>Zeisel</surname><given-names>SH</given-names></name></person-group>
<year>1993</year>
<article-title>Lipid synthesis and secretion by primary cultures of rat mammary epithelial cells.</article-title>
<source>J. Cell Physiol</source>
<volume>157</volume>
<fpage>469</fpage>
<lpage>480</lpage>
<pub-id pub-id-type="pmid">8253858</pub-id></element-citation></ref><ref id="pone.0003003-Way1"><label>82</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Way</surname><given-names>KJ</given-names></name><name><surname>Katai</surname><given-names>N</given-names></name><name><surname>King</surname><given-names>GL</given-names></name></person-group>
<year>2001</year>
<article-title>Protein kinase C and the development of diabetic vascular complications.</article-title>
<source>Diabet. Med</source>
<volume>18</volume>
<fpage>945</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="pmid">11903393</pub-id></element-citation></ref><ref id="pone.0003003-Bozza1"><label>83</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bozza</surname><given-names>PT</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Penrose</surname><given-names>JF</given-names></name><name><surname>Morgan</surname><given-names>ES</given-names></name><name><surname>Dvorak</surname><given-names>AM</given-names></name><etal/></person-group>
<year>1997</year>
<article-title>Eosinophil lipid bodies: specific, inducible intracellular sites for enhanced eicosanoid formation.</article-title>
<source>J. Exp. Med</source>
<volume>186</volume>
<fpage>909</fpage>
<lpage>920</lpage>
<pub-id pub-id-type="pmid">9294145</pub-id></element-citation></ref><ref id="pone.0003003-Parkes1"><label>84</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parkes</surname><given-names>HA</given-names></name><name><surname>Preston</surname><given-names>E</given-names></name><name><surname>Wilks</surname><given-names>D</given-names></name><name><surname>Ballesteros</surname><given-names>M</given-names></name><name><surname>Carpenter</surname><given-names>L</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Overexpression of acyl-CoA synthetase-1 increases lipid deposition in hepatic (HepG2) cells and rodent liver in vivo.</article-title>
<source>Am. J. Physiol Endocrinol. Metab</source>
<volume>291</volume>
<fpage>E737</fpage>
<lpage>E744</lpage>
<pub-id pub-id-type="pmid">16705061</pub-id></element-citation></ref><ref id="pone.0003003-Tong1"><label>85</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tong</surname><given-names>F</given-names></name><name><surname>Black</surname><given-names>PN</given-names></name><name><surname>Coleman</surname><given-names>RA</given-names></name><name><surname>DiRusso</surname><given-names>CC</given-names></name></person-group>
<year>2006</year>
<article-title>Fatty acid transport by vectorial acylation in mammals: roles played by different isoforms of rat long-chain acyl-CoA synthetases.</article-title>
<source>Arch. Biochem. Biophys</source>
<volume>447</volume>
<fpage>46</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">16466685</pub-id></element-citation></ref><ref id="pone.0003003-Siegenthaler1"><label>86</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siegenthaler</surname><given-names>G</given-names></name><name><surname>Hotz</surname><given-names>R</given-names></name><name><surname>Chatellard-Gruaz</surname><given-names>D</given-names></name><name><surname>Didierjean</surname><given-names>L</given-names></name><name><surname>Hellman</surname><given-names>U</given-names></name><etal/></person-group>
<year>1994</year>
<article-title>Purification and characterization of the human epidermal fatty acid-binding protein: localization during epidermal cell differentiation in vivo and in vitro.</article-title>
<source>Biochem. J</source>
<volume>302</volume>
<fpage>363</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="pmid">8092987</pub-id></element-citation></ref><ref id="pone.0003003-Hertzel1"><label>87</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hertzel</surname><given-names>AV</given-names></name><name><surname>naars-Eiden</surname><given-names>A</given-names></name><name><surname>Bernlohr</surname><given-names>DA</given-names></name></person-group>
<year>2002</year>
<article-title>Increased lipolysis in transgenic animals overexpressing the epithelial fatty acid binding protein in adipose cells.</article-title>
<source>J. Lipid Res</source>
<volume>43</volume>
<fpage>2105</fpage>
<lpage>2111</lpage>
<pub-id pub-id-type="pmid">12454272</pub-id></element-citation></ref><ref id="pone.0003003-LlorenteCortes1"><label>88</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Llorente-Cortes</surname><given-names>V</given-names></name><name><surname>Badimon</surname><given-names>L</given-names></name></person-group>
<year>2005</year>
<article-title>LDL receptor-related protein and the vascular wall: implications for atherothrombosis.</article-title>
<source>Arterioscler. Thromb. Vasc. Biol</source>
<volume>25</volume>
<fpage>497</fpage>
<lpage>504</lpage>
<pub-id pub-id-type="pmid">15705932</pub-id></element-citation></ref><ref id="pone.0003003-May1"><label>89</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>May</surname><given-names>P</given-names></name><name><surname>Woldt</surname><given-names>E</given-names></name><name><surname>Matz</surname><given-names>RL</given-names></name><name><surname>Boucher</surname><given-names>P</given-names></name></person-group>
<year>2007</year>
<article-title>The LDL receptor-related protein (LRP) family: an old family of proteins with new physiological functions.</article-title>
<source>Ann. Med</source>
<volume>39</volume>
<fpage>219</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="pmid">17457719</pub-id></element-citation></ref><ref id="pone.0003003-Chappell1"><label>90</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chappell</surname><given-names>DA</given-names></name><name><surname>Fry</surname><given-names>GL</given-names></name><name><surname>Waknitz</surname><given-names>MA</given-names></name><name><surname>Muhonen</surname><given-names>LE</given-names></name><name><surname>Pladet</surname><given-names>MW</given-names></name><etal/></person-group>
<year>1993</year>
<article-title>Lipoprotein lipase induces catabolism of normal triglyceride-rich lipoproteins via the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor in vitro. A process facilitated by cell-surface proteoglycans.</article-title>
<source>J. Biol Chem</source>
<volume>268</volume>
<fpage>14168</fpage>
<lpage>14175</lpage>
<pub-id pub-id-type="pmid">8314783</pub-id></element-citation></ref><ref id="pone.0003003-CaminoLopez1"><label>91</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Camino-Lopez</surname><given-names>S</given-names></name><name><surname>Llorente-Cortes</surname><given-names>V</given-names></name><name><surname>Sendra</surname><given-names>J</given-names></name><name><surname>Badimon</surname><given-names>L</given-names></name></person-group>
<year>2007</year>
<article-title>Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells.</article-title>
<source>Cardiovasc. Res</source>
<volume>73</volume>
<fpage>208</fpage>
<lpage>216</lpage>
<pub-id pub-id-type="pmid">17141748</pub-id></element-citation></ref><ref id="pone.0003003-LlorenteCortes2"><label>92</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Llorente-Cortes</surname><given-names>V</given-names></name><name><surname>Royo</surname><given-names>T</given-names></name><name><surname>Juan-Babot</surname><given-names>O</given-names></name><name><surname>Badimon</surname><given-names>L</given-names></name></person-group>
<year>2007</year>
<article-title>Adipocyte differentiation-related protein is induced by LRP1-mediated aggregated LDL internalization in human vascular smooth muscle cells and macrophages.</article-title>
<source>J. Lipid Res</source>
<volume>48</volume>
<fpage>2133</fpage>
<lpage>2140</lpage>
<pub-id pub-id-type="pmid">17620659</pub-id></element-citation></ref><ref id="pone.0003003-LlorenteCortes3"><label>93</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Llorente-Cortes</surname><given-names>V</given-names></name><name><surname>Royo</surname><given-names>T</given-names></name><name><surname>Otero-Vinas</surname><given-names>M</given-names></name><name><surname>Berrozpe</surname><given-names>M</given-names></name><name><surname>Badimon</surname><given-names>L</given-names></name></person-group>
<year>2007</year>
<article-title>Sterol regulatory element binding proteins downregulate LDL receptor-related protein (LRP1) expression and LRP1-mediated aggregated LDL uptake by human macrophages.</article-title>
<source>Cardiovasc. Res</source>
<volume>74</volume>
<fpage>526</fpage>
<lpage>536</lpage>
<pub-id pub-id-type="pmid">17376415</pub-id></element-citation></ref><ref id="pone.0003003-EspiritoSanto1"><label>94</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Espirito Santo</surname><given-names>SM</given-names></name><name><surname>Rensen</surname><given-names>PC</given-names></name><name><surname>Goudriaan</surname><given-names>JR</given-names></name><name><surname>Bensadoun</surname><given-names>A</given-names></name><name><surname>Bovenschen</surname><given-names>N</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Triglyceride-rich lipoprotein metabolism in unique VLDL receptor, LDL receptor, and LRP triple-deficient mice.</article-title>
<source>J. Lipid Res</source>
<volume>46</volume>
<fpage>1097</fpage>
<lpage>1102</lpage>
<pub-id pub-id-type="pmid">15772433</pub-id></element-citation></ref><ref id="pone.0003003-Xu2"><label>95</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Sakashita</surname><given-names>T</given-names></name><name><surname>Iwasaki</surname><given-names>T</given-names></name><name><surname>Hattori</surname><given-names>H</given-names></name><etal/></person-group>
<year>2001</year>
<article-title>Low density lipoprotein receptor-related protein is required for macrophage-mediated oxidation of low density lipoprotein by 12/15-lipoxygenase.</article-title>
<source>J. Biol Chem</source>
<volume>276</volume>
<fpage>36454</fpage>
<lpage>36459</lpage>
<pub-id pub-id-type="pmid">11479307</pub-id></element-citation></ref><ref id="pone.0003003-Domingo1"><label>96</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Domingo</surname><given-names>P</given-names></name><name><surname>Sambeat</surname><given-names>MA</given-names></name><name><surname>Perez</surname><given-names>A</given-names></name><name><surname>Ordonez</surname><given-names>J</given-names></name></person-group>
<year>2003</year>
<article-title>Effect of protease inhibitors on apolipoprotein B levels and plasma lipid profile in HIV-1-infected patients on highly active antiretroviral therapy.</article-title>
<source>J. Acquir. Immune. Defic. Syndr</source>
<volume>33</volume>
<fpage>114</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="pmid">12792364</pub-id></element-citation></ref><ref id="pone.0003003-Das1"><label>97</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Shahmanesh</surname><given-names>M</given-names></name><name><surname>Stolinski</surname><given-names>M</given-names></name><name><surname>Shojaee-Moradie</surname><given-names>F</given-names></name><name><surname>Jefferson</surname><given-names>W</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>In treatment-naive and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100.</article-title>
<source>Diabetologia</source>
<volume>49</volume>
<fpage>538</fpage>
<lpage>542</lpage>
<pub-id pub-id-type="pmid">16432707</pub-id></element-citation></ref><ref id="pone.0003003-MacDougall1"><label>98</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>MacDougall</surname><given-names>ED</given-names></name><name><surname>Kramer</surname><given-names>F</given-names></name><name><surname>Polinsky</surname><given-names>P</given-names></name><name><surname>Barnhart</surname><given-names>S</given-names></name><name><surname>Askari</surname><given-names>B</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Aggressive very low-density lipoprotein (VLDL) and LDL lowering by gene transfer of the VLDL receptor combined with a low-fat diet regimen induces regression and reduces macrophage content in advanced atherosclerotic lesions in LDL receptor-deficient mice.</article-title>
<source>Am. J. Pathol</source>
<volume>168</volume>
<fpage>2064</fpage>
<lpage>2073</lpage>
<pub-id pub-id-type="pmid">16723719</pub-id></element-citation></ref><ref id="pone.0003003-Shelness1"><label>99</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shelness</surname><given-names>GS</given-names></name><name><surname>Sellers</surname><given-names>JA</given-names></name></person-group>
<year>2001</year>
<article-title>Very-low-density lipoprotein assembly and secretion.</article-title>
<source>Curr. Opin. Lipidol</source>
<volume>12</volume>
<fpage>151</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="pmid">11264986</pub-id></element-citation></ref><ref id="pone.0003003-Shahmanesh1"><label>100</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shahmanesh</surname><given-names>M</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Stolinski</surname><given-names>M</given-names></name><name><surname>Shojaee-Moradie</surname><given-names>F</given-names></name><name><surname>Jackson</surname><given-names>NC</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia.</article-title>
<source>J. Clin. Endocrinol. Metab</source>
<volume>90</volume>
<fpage>755</fpage>
<lpage>760</lpage>
<pub-id pub-id-type="pmid">15522931</pub-id></element-citation></ref><ref id="pone.0003003-Carpentier1"><label>101</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carpentier</surname><given-names>A</given-names></name><name><surname>Patterson</surname><given-names>BW</given-names></name><name><surname>Uffelman</surname><given-names>KD</given-names></name><name><surname>Salit</surname><given-names>I</given-names></name><name><surname>Lewis</surname><given-names>GF</given-names></name></person-group>
<year>2005</year>
<article-title>Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals.</article-title>
<source>Atherosclerosis</source>
<volume>178</volume>
<fpage>165</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="pmid">15585214</pub-id></element-citation></ref><ref id="pone.0003003-Packard1"><label>102</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Packard</surname><given-names>CJ</given-names></name><name><surname>Demant</surname><given-names>T</given-names></name><name><surname>Stewart</surname><given-names>JP</given-names></name><name><surname>Bedford</surname><given-names>D</given-names></name><name><surname>Caslake</surname><given-names>MJ</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.</article-title>
<source>J. Lipid Res</source>
<volume>41</volume>
<fpage>305</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="pmid">10681415</pub-id></element-citation></ref><ref id="pone.0003003-Olofsson1"><label>103</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olofsson</surname><given-names>SO</given-names></name><name><surname>Boren</surname><given-names>J</given-names></name></person-group>
<year>2005</year>
<article-title>Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis.</article-title>
<source>J. Intern. Med</source>
<volume>258</volume>
<fpage>395</fpage>
<lpage>410</lpage>
<pub-id pub-id-type="pmid">16238675</pub-id></element-citation></ref><ref id="pone.0003003-Yamaguchi1"><label>104</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>J</given-names></name><name><surname>Gamble</surname><given-names>MV</given-names></name><name><surname>Conlon</surname><given-names>D</given-names></name><name><surname>Liang</surname><given-names>JS</given-names></name><name><surname>Ginsberg</surname><given-names>HN</given-names></name></person-group>
<year>2003</year>
<article-title>The conversion of apoB100 low density lipoprotein/high density lipoprotein particles to apoB100 very low density lipoproteins in response to oleic acid occurs in the endoplasmic reticulum and not in the Golgi in McA RH7777 cells.</article-title>
<source>J. Biol Chem</source>
<volume>278</volume>
<fpage>42643</fpage>
<lpage>42651</lpage>
<pub-id pub-id-type="pmid">12917397</pub-id></element-citation></ref><ref id="pone.0003003-Feingold1"><label>105</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feingold</surname><given-names>KR</given-names></name><name><surname>Krauss</surname><given-names>RM</given-names></name><name><surname>Pang</surname><given-names>M</given-names></name><name><surname>Doerrler</surname><given-names>W</given-names></name><name><surname>Jensen</surname><given-names>P</given-names></name><etal/></person-group>
<year>1993</year>
<article-title>The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J.</article-title>
<source>Clin. Endocrinol. Metab</source>
<volume>76</volume>
<fpage>1423</fpage>
<lpage>1427</lpage>
</element-citation></ref><ref id="pone.0003003-Leroy1"><label>106</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leroy</surname><given-names>A</given-names></name><name><surname>Dallongeville</surname><given-names>J</given-names></name><name><surname>Fruchart</surname><given-names>JC</given-names></name></person-group>
<year>1995</year>
<article-title>Apolipoprotein A-I-containing lipoproteins and atherosclerosis.</article-title>
<source>Curr. Opin. Lipidol</source>
<volume>6</volume>
<fpage>281</fpage>
<lpage>285</lpage>
<pub-id pub-id-type="pmid">8520850</pub-id></element-citation></ref><ref id="pone.0003003-Chulkova1"><label>107</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chulkova</surname><given-names>TM</given-names></name><name><surname>Tertov</surname><given-names>VV</given-names></name></person-group>
<year>1993</year>
<article-title>Degradation of human apolipoprotein B-100 by apolipoprotein(a).</article-title>
<source>FEBS Lett</source>
<volume>336</volume>
<fpage>327</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="pmid">8262255</pub-id></element-citation></ref><ref id="pone.0003003-Srinivas1"><label>108</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srinivas</surname><given-names>RV</given-names></name><name><surname>Birkedal</surname><given-names>B</given-names></name><name><surname>Owens</surname><given-names>RJ</given-names></name><name><surname>Anantharamaiah</surname><given-names>GM</given-names></name><name><surname>Segrest</surname><given-names>JP</given-names></name><etal/></person-group>
<year>1990</year>
<article-title>Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs.</article-title>
<source>Virology</source>
<volume>176</volume>
<fpage>48</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="pmid">2158697</pub-id></element-citation></ref><ref id="pone.0003003-Panin1"><label>109</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Panin</surname><given-names>LE</given-names></name><name><surname>Kostina</surname><given-names>NE</given-names></name></person-group>
<year>2003</year>
<article-title>[Interaction of human apolipoprotein AI and HIV-1 envelope proteins with the native and recombinant CD4 receptors].</article-title>
<source>Vopr. Virusol</source>
<volume>48</volume>
<fpage>24</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="pmid">12608057</pub-id></element-citation></ref><ref id="pone.0003003-Kim1"><label>110</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>SS</given-names></name><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Shin</surname><given-names>BK</given-names></name><name><surname>Na</surname><given-names>HJ</given-names></name><name><surname>Choi</surname><given-names>JY</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Different isoforms of apolipoprotein AI present heterologous post-translational expression in HIV infected patients.</article-title>
<source>J. Proteome. Res</source>
<volume>6</volume>
<fpage>180</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="pmid">17203962</pub-id></element-citation></ref><ref id="pone.0003003-Curry1"><label>111</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Curry</surname><given-names>S</given-names></name><name><surname>Mandelkow</surname><given-names>H</given-names></name><name><surname>Brick</surname><given-names>P</given-names></name><name><surname>Franks</surname><given-names>N</given-names></name></person-group>
<year>1998</year>
<article-title>Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites.</article-title>
<source>Nat. Struct. Biol</source>
<volume>5</volume>
<fpage>827</fpage>
<lpage>835</lpage>
<pub-id pub-id-type="pmid">9731778</pub-id></element-citation></ref><ref id="pone.0003003-Fujiwara1"><label>112</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fujiwara</surname><given-names>S</given-names></name><name><surname>Amisaki</surname><given-names>T</given-names></name></person-group>
<year>2008</year>
<article-title>Identification of high affinity fatty acid binding sites on human serum albumin by MM-PBSA method.</article-title>
<source>Biophys. J</source>
<volume>94</volume>
<fpage>95</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="pmid">17827235</pub-id></element-citation></ref><ref id="pone.0003003-Dadaian1"><label>113</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dadaian</surname><given-names>M</given-names></name><name><surname>Westlund</surname><given-names>P</given-names></name></person-group>
<year>1999</year>
<article-title>Albumin modifies the metabolism of hydroxyeicosatetraenoic acids via 12-lipoxygenase in human platelets.</article-title>
<source>J. Lipid Res</source>
<volume>40</volume>
<fpage>940</fpage>
<lpage>947</lpage>
<pub-id pub-id-type="pmid">10224163</pub-id></element-citation></ref><ref id="pone.0003003-Ha1"><label>114</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ha</surname><given-names>JS</given-names></name><name><surname>Theriault</surname><given-names>A</given-names></name><name><surname>Bhagavan</surname><given-names>NV</given-names></name><name><surname>Ha</surname><given-names>CE</given-names></name></person-group>
<year>2006</year>
<article-title>Fatty acids bound to human serum albumin and its structural variants modulate apolipoprotein B secretion in HepG2 cells.</article-title>
<source>Biochim. Biophys. Acta</source>
<volume>1761</volume>
<fpage>717</fpage>
<lpage>724</lpage>
<pub-id pub-id-type="pmid">16843720</pub-id></element-citation></ref><ref id="pone.0003003-Anderson2"><label>115</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anderson</surname><given-names>DR</given-names></name><name><surname>Tsutsui</surname><given-names>JM</given-names></name><name><surname>Xie</surname><given-names>F</given-names></name><name><surname>Radio</surname><given-names>SJ</given-names></name><name><surname>Porter</surname><given-names>TR</given-names></name></person-group>
<year>2007</year>
<article-title>The role of complement in the adherence of microbubbles to dysfunctional arterial endothelium and atherosclerotic plaque.</article-title>
<source>Cardiovasc. Res</source>
<volume>73</volume>
<fpage>597</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="pmid">17196951</pub-id></element-citation></ref><ref id="pone.0003003-Huang1"><label>116</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Atshaves</surname><given-names>BP</given-names></name><name><surname>Frolov</surname><given-names>A</given-names></name><name><surname>Kier</surname><given-names>AB</given-names></name><name><surname>Schroeder</surname><given-names>F</given-names></name></person-group>
<year>2005</year>
<article-title>Acyl-coenzyme A binding protein expression alters liver fatty acyl-coenzyme A metabolism.</article-title>
<source>Biochemistry</source>
<volume>44</volume>
<fpage>10282</fpage>
<lpage>10297</lpage>
<pub-id pub-id-type="pmid">16042405</pub-id></element-citation></ref><ref id="pone.0003003-Mandrup1"><label>117</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mandrup</surname><given-names>S</given-names></name><name><surname>Sorensen</surname><given-names>RV</given-names></name><name><surname>Helledie</surname><given-names>T</given-names></name><name><surname>Nohr</surname><given-names>J</given-names></name><name><surname>Baldursson</surname><given-names>T</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>Inhibition of 3T3-L1 adipocyte differentiation by expression of acyl-CoA-binding protein antisense RNA.</article-title>
<source>J. Biol Chem</source>
<volume>273</volume>
<fpage>23897</fpage>
<lpage>23903</lpage>
<pub-id pub-id-type="pmid">9727003</pub-id></element-citation></ref><ref id="pone.0003003-Lee1"><label>118</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>L</given-names></name><name><surname>DeBono</surname><given-names>CA</given-names></name><name><surname>Campagna</surname><given-names>DR</given-names></name><name><surname>Young</surname><given-names>DC</given-names></name><name><surname>Moody</surname><given-names>DB</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Loss of the acyl-CoA binding protein (Acbp) results in fatty acid metabolism abnormalities in mouse hair and skin.</article-title>
<source>J. Invest Dermatol</source>
<volume>127</volume>
<fpage>16</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">16902415</pub-id></element-citation></ref><ref id="pone.0003003-Lamberg1"><label>119</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lamberg</surname><given-names>A</given-names></name><name><surname>Jauhiainen</surname><given-names>M</given-names></name><name><surname>Metso</surname><given-names>J</given-names></name><name><surname>Ehnholm</surname><given-names>C</given-names></name><name><surname>Shoulders</surname><given-names>C</given-names></name><etal/></person-group>
<year>1996</year>
<article-title>The role of protein disulphide isomerase in the microsomal triacylglycerol transfer protein does not reside in its isomerase activity.</article-title>
<source>Biochem. J</source>
<volume>315</volume>
<fpage>533</fpage>
<lpage>536</lpage>
<pub-id pub-id-type="pmid">8615825</pub-id></element-citation></ref><ref id="pone.0003003-Peden1"><label>120</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peden</surname><given-names>K</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name><name><surname>Montagnier</surname><given-names>L</given-names></name></person-group>
<year>1991</year>
<article-title>Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI.</article-title>
<source>Virology</source>
<volume>185</volume>
<fpage>661</fpage>
<lpage>672</lpage>
<pub-id pub-id-type="pmid">1683726</pub-id></element-citation></ref><ref id="pone.0003003-CharnockJones1"><label>121</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Charnock-Jones</surname><given-names>DS</given-names></name><name><surname>Day</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>SK</given-names></name></person-group>
<year>1996</year>
<article-title>Cloning, expression and genomic organization of human placental protein disulfide isomerase (previously identified as phospholipase C alpha).</article-title>
<source>Int. J. Biochem. Cell Biol</source>
<volume>28</volume>
<fpage>81</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="pmid">8624847</pub-id></element-citation></ref><ref id="pone.0003003-Burch1"><label>122</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burch</surname><given-names>WL</given-names></name><name><surname>Herscovitz</surname><given-names>H</given-names></name></person-group>
<year>2000</year>
<article-title>Disulfide bonds are required for folding and secretion of apolipoprotein B regardless of its lipidation state.</article-title>
<source>J. Biol Chem</source>
<volume>275</volume>
<fpage>16267</fpage>
<lpage>16274</lpage>
<pub-id pub-id-type="pmid">10747912</pub-id></element-citation></ref><ref id="pone.0003003-Rehberg1"><label>123</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rehberg</surname><given-names>EF</given-names></name><name><surname>Samson-Bouma</surname><given-names>ME</given-names></name><name><surname>Kienzle</surname><given-names>B</given-names></name><name><surname>Blinderman</surname><given-names>L</given-names></name><name><surname>Jamil</surname><given-names>H</given-names></name><etal/></person-group>
<year>1996</year>
<article-title>A novel abetalipoproteinemia genotype. Identification of a missense mutation in the 97-kDa subunit of the microsomal triglyceride transfer protein that prevents complex formation with protein disulfide isomerase.</article-title>
<source>J. Biol Chem</source>
<volume>271</volume>
<fpage>29945</fpage>
<lpage>29952</lpage>
<pub-id pub-id-type="pmid">8939939</pub-id></element-citation></ref><ref id="pone.0003003-Mizrak1"><label>124</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mizrak</surname><given-names>SC</given-names></name><name><surname>Bogerd</surname><given-names>J</given-names></name><name><surname>Lopez-Casas</surname><given-names>PP</given-names></name><name><surname>Parraga</surname><given-names>M</given-names></name><name><surname>Del</surname><given-names>MJ</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Expression of stress inducible protein 1 (Stip1) in the mouse testis.</article-title>
<source>Mol. Reprod Dev</source>
<volume>73</volume>
<fpage>1361</fpage>
<lpage>1366</lpage>
<pub-id pub-id-type="pmid">16894550</pub-id></element-citation></ref><ref id="pone.0003003-Longshaw1"><label>125</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Longshaw</surname><given-names>VM</given-names></name><name><surname>Chapple</surname><given-names>JP</given-names></name><name><surname>Balda</surname><given-names>MS</given-names></name><name><surname>Cheetham</surname><given-names>ME</given-names></name><name><surname>Blatch</surname><given-names>GL</given-names></name></person-group>
<year>2004</year>
<article-title>Nuclear translocation of the Hsp70/Hsp90 organizing protein mSTI1 is regulated by cell cycle kinases.</article-title>
<source>J. Cell Sci</source>
<volume>117</volume>
<fpage>701</fpage>
<lpage>710</lpage>
<pub-id pub-id-type="pmid">14754904</pub-id></element-citation></ref><ref id="pone.0003003-Gao1"><label>126</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>T</given-names></name><name><surname>Newton</surname><given-names>AC</given-names></name></person-group>
<year>2002</year>
<article-title>The turn motif is a phosphorylation switch that regulates the binding of Hsp70 to protein kinase C.</article-title>
<source>J. Biol Chem</source>
<volume>277</volume>
<fpage>31585</fpage>
<lpage>31592</lpage>
<pub-id pub-id-type="pmid">12080070</pub-id></element-citation></ref><ref id="pone.0003003-Hashiguchi1"><label>127</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hashiguchi</surname><given-names>N</given-names></name><name><surname>Ogura</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Koh</surname><given-names>T</given-names></name><name><surname>Nakamori</surname><given-names>Y</given-names></name><etal/></person-group>
<year>2001</year>
<article-title>Enhanced expression of heat shock proteins in activated polymorphonuclear leukocytes in patients with sepsis.</article-title>
<source>J. Trauma</source>
<volume>51</volume>
<fpage>1104</fpage>
<lpage>1109</lpage>
<pub-id pub-id-type="pmid">11740261</pub-id></element-citation></ref><ref id="pone.0003003-Chen1"><label>128</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>DF</given-names></name></person-group>
<year>1998</year>
<article-title>Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery.</article-title>
<source>J. Biol Chem</source>
<volume>273</volume>
<fpage>35194</fpage>
<lpage>35200</lpage>
<pub-id pub-id-type="pmid">9857057</pub-id></element-citation></ref><ref id="pone.0003003-Smith1"><label>129</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>DF</given-names></name><name><surname>Sullivan</surname><given-names>WP</given-names></name><name><surname>Marion</surname><given-names>TN</given-names></name><name><surname>Zaitsu</surname><given-names>K</given-names></name><name><surname>Madden</surname><given-names>B</given-names></name><etal/></person-group>
<year>1993</year>
<article-title>Identification of a 60-kilodalton stress-related protein, p60, which interacts with hsp90 and hsp70.</article-title>
<source>Mol. Cell Biol</source>
<volume>13</volume>
<fpage>869</fpage>
<lpage>876</lpage>
<pub-id pub-id-type="pmid">8423808</pub-id></element-citation></ref><ref id="pone.0003003-Chakraborty1"><label>130</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>A</given-names></name><name><surname>Koldobskiy</surname><given-names>MA</given-names></name><name><surname>Sixt</surname><given-names>KM</given-names></name><name><surname>Juluri</surname><given-names>KR</given-names></name><name><surname>Mustafa</surname><given-names>AK</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>From the Cover: HSP90 regulates cell survival via inositol hexakisphosphate kinase-2.</article-title>
<source>PNAS</source>
<volume>105</volume>
<fpage>1134</fpage>
<lpage>1139</lpage>
<pub-id pub-id-type="pmid">18195352</pub-id></element-citation></ref><ref id="pone.0003003-Pratt1"><label>131</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pratt</surname><given-names>WB</given-names></name><name><surname>Toft</surname><given-names>DO</given-names></name></person-group>
<year>1997</year>
<article-title>Steroid receptor interactions with heat shock protein and immunophilin chaperones.</article-title>
<source>Endocr. Rev</source>
<volume>18</volume>
<fpage>306</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="pmid">9183567</pub-id></element-citation></ref><ref id="pone.0003003-Floer1"><label>132</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Floer</surname><given-names>M</given-names></name><name><surname>Bryant</surname><given-names>GO</given-names></name><name><surname>Ptashne</surname><given-names>M</given-names></name></person-group>
<year>2008</year>
<article-title>HSP90/70 chaperones are required for rapid nucleosome removal upon induction of the GAL genes of yeast.</article-title>
<source>PNAS</source>
<volume>105</volume>
<fpage>2975</fpage>
<lpage>2980</lpage>
<pub-id pub-id-type="pmid">18287040</pub-id></element-citation></ref><ref id="pone.0003003-Pratt2"><label>133</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pratt</surname><given-names>WB</given-names></name><name><surname>Toft</surname><given-names>DO</given-names></name></person-group>
<year>2003</year>
<article-title>Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery.</article-title>
<source>Exp. Biol Med. (Maywood.)</source>
<volume>228</volume>
<fpage>111</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="pmid">12563018</pub-id></element-citation></ref><ref id="pone.0003003-Freeman1"><label>134</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Freeman</surname><given-names>BC</given-names></name><name><surname>Yamamoto</surname><given-names>KR</given-names></name></person-group>
<year>2002</year>
<article-title>Disassembly of transcriptional regulatory complexes by molecular chaperones.</article-title>
<source>Science</source>
<volume>296</volume>
<fpage>2232</fpage>
<lpage>2235</lpage>
<pub-id pub-id-type="pmid">12077419</pub-id></element-citation></ref><ref id="pone.0003003-Chambon1"><label>135</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chambon</surname><given-names>M</given-names></name><name><surname>Rochefort</surname><given-names>H</given-names></name><name><surname>Vial</surname><given-names>HJ</given-names></name><name><surname>Chalbos</surname><given-names>D</given-names></name></person-group>
<year>1989</year>
<article-title>Progestins and androgens stimulate lipid accumulation in T47D breast cancer cells via their own receptors.</article-title>
<source>J. Steroid Biochem</source>
<volume>33</volume>
<fpage>915</fpage>
<lpage>922</lpage>
<pub-id pub-id-type="pmid">2601336</pub-id></element-citation></ref><ref id="pone.0003003-Knowlton1"><label>136</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Knowlton</surname><given-names>AA</given-names></name><name><surname>Kapadia</surname><given-names>S</given-names></name><name><surname>Torre-Amione</surname><given-names>G</given-names></name><name><surname>Durand</surname><given-names>JB</given-names></name><name><surname>Bies</surname><given-names>R</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>Differential expression of heat shock proteins in normal and failing human hearts.</article-title>
<source>J. Mol. Cell Cardiol</source>
<volume>30</volume>
<fpage>811</fpage>
<lpage>818</lpage>
<pub-id pub-id-type="pmid">9602430</pub-id></element-citation></ref><ref id="pone.0003003-Wright1"><label>137</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wright</surname><given-names>D</given-names></name><name><surname>Rodriguez</surname><given-names>A</given-names></name><name><surname>Godofsky</surname><given-names>E</given-names></name><name><surname>Walmsley</surname><given-names>S</given-names></name><name><surname>Labriola-Tompkins</surname><given-names>E</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Impact of Switching Virologically Suppressed, HIV-1-Infected Patients from Twice-Daily Fixed-Dose Zidovudine/Lamivudine to Once-Daily Fixed-Dose Tenofovir Disoproxil Fumarate/Emtricitabine.</article-title>
<source>HIV. Clin. Trials</source>
<volume>9</volume>
<fpage>103</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="pmid">18474495</pub-id></element-citation></ref><ref id="pone.0003003-Park3"><label>138</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>SS</given-names></name><name><surname>Hong</surname><given-names>SK</given-names></name><name><surname>Lee</surname><given-names>SG</given-names></name><name><surname>Yoon</surname><given-names>JS</given-names></name><name><surname>Yoo</surname><given-names>WC</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>In vitro selection and characterization of human immunodeficiency virus type 1 resistant to Zidovudine and tenofovir.</article-title>
<source>Nucleosides Nucleotides Nucleic Acids</source>
<volume>26</volume>
<fpage>453</fpage>
<lpage>457</lpage>
<pub-id pub-id-type="pmid">17578743</pub-id></element-citation></ref><ref id="pone.0003003-Rasheed2"><label>139</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rasheed</surname><given-names>S</given-names></name><name><surname>Mao</surname><given-names>Z</given-names></name><name><surname>Chan</surname><given-names>JM</given-names></name><name><surname>Chan</surname><given-names>LS</given-names></name></person-group>
<year>2005</year>
<article-title>Is Melanoma a stem cell tumor? Identification of neurogenic proteins in trans-differentiated cells.</article-title>
<source>J. Transl. Med</source>
<volume>3</volume>
<fpage>14</fpage>
<pub-id pub-id-type="pmid">15784142</pub-id></element-citation></ref></ref-list></back></article>